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Summary  
“Population ageing” - the process by which older individuals make up a 
proportionally larger share of the total population over a period of time has thrown 
up new challenges such as the increasing demand and expense on health and social 
care. Cardiovascular disease, prevalent in older people, goes hand in hand with 
declining physical function and new ways of tackling the burden this places on older 
persons, their carers and health services are required.  
 
Recent work has suggested that vitamin K, a known cofactor for coagulation 
proteins, may be required for the function of several other key proteins. In particular, 
Matrix Gla protein may exert beneficial effects on vascular health. I hypothesised 
that supplementation of the diet with vitamin K would improve vascular health and 
physical function in older people with established vascular disease. 
 
In a double-blind randomised controlled clinical trial 80 participants aged ≥ 70years 
with established vascular disease were randomised to receive 100mcg vitamin K or 
placebo daily for 6 months. The primary outcome was a between group difference in 
endothelial function change between baseline and 6 months. The secondary 
outcomes were carotid-radial pulse wave velocity, carotid intima-media thickness, 
Short Physical Performance Battery and grip strength.  
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Participant mean age was 77 years (SD 5), 44/80 (55%) were male. Only 3/80 (4%) 
participants failed to complete the study. Vitamin K levels rose in the intervention 
arm compared to placebo (+48pg/ml vs. -6pg/ml, p=0.03) at six months compared to 
baseline.  There was no significant change in brachial artery flow mediated dilatation 
or indeed in any of the other markers of vascular health or physical function. This 
was despite excellent adherence to medication. There was however a modest 10% 
reduction in arterial stiffness by 6 months suggesting that changes to vascular 
calcification with vitamin K2 may be possible but may require longer to achieve.
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1. LITERATURE REVIEW 
1.1 The Discovery of Vitamins 
For centuries the belief that diseases were due to the presence of some type of 
organism rather than a dietary deficiency prohibited the treatment of illness such as 
beriberi (a deficiency of vitamin B1), rickets (a deficiency of vitamin D) and scurvy 
(a deficiency of vitamin C) 
(1)
. The earliest studies by Lunin in 1881 and Pekelharing 
in 1905 
(1)
 examined the response of laboratory animals to an artificial diet 
comprising protein, fat, carbohydrate minerals and water. In both studies there was 
failure to thrive and death among the mice, but milk, even when ingested in small 
quantities, seemed to keep the mice alive 
(2)
. By 1912 Casimir Funk had formulated 
the theory that certain diseases could be prevented by ingestion of a complete diet 
including these accessory factors, and classified these substances Vita “life” and 
amine a compound containing nitrogen, reflecting the fact that the first of the 
vitamins to be studied was vitamin B1 
(3)
. Two of the fat soluble vitamins were 
discovered in 1913 – vitamin A which was effective in preventing Xerophthalmia 
(dry eye syndrome) and vitamin D which was effective against rickets. 
 
By 1920 it had become clear that not all vitamins were amines so the “e” on the end 
was dropped.  
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Vitamin subgroups 
By 1915 Osborne and Mendal and McCollum and Davis had distinguished two types 
of accessory factors based on their solubilities  – Fat soluble A which is present in 
butterfat and egg yolk and the previously identified water soluble B.  Most vitamins 
were identified between 1920 and 1950 and over the past century the importance of 
theses food factors for normal growth and metabolism has been established 
(4;5)
.   
 
In total thirteen vitamins are currently recognised in human nutrition – the four fat 
soluble vitamins A, D, E and K and the nine water soluble vitamins comprising of 
vitamin C and the eight members of the vitamin B group – thiamine (B1), riboflavin 
(B2), niacin (B3), pantothenic acid (B5), pyridoxine (B6), biotin (B7), folic acid (B9) 
and cobalamin (B12). 
 
Action 
Most vitamins act as co-enzymes, promoting catalytic functions in the body’s 
metabolic pathways.  At least 30 vitamins and minerals (micronutrients) are required 
by the body.  Sometimes a number of vitamins and minerals must interact to 
accomplish these metabolic functions: for example for optimum absorption of the 
mineral calcium in bone health the vitamin D must also be available, while for 
promotion of good vision the absorption of vitamin A improves in the presence of 
the mineral zinc. No single foodstuff provides all the micronutrients required.   
 
Today, compared to the dates of their discovery, intake of these micronutrients is 
much improved. While some of the deficiency conditions such as beriberi and scurvy 
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are rare in the UK, rickets may still be evident in socially deprived groups 
(6)
 and in 
Asian children with darkly pigmented skin. 
 
1.2 Vitamin K 
A Historical view 
The function and properties of blood were the subject of debate as long ago as the 
time of Hippocrates in 460BC and by AD1832 Johannes Muller described the role of 
fibrin in clotting 
(7)
.  
 
Danish biochemist Henrik Dam first discovered the nutrient vitamin K while 
carrying out studies in the 1930s while investigating the need for cholesterol in the 
diet of chicks 
(7;8)
.  Chicks fed a diet from which sterols had been removed developed 
internal bleeding and died. On examining the dead chicks, their blood was found to 
clot slowly.  Further experiments involving the addition of different foodstuffs found 
that the ‘antihaemorrhagic (or clotting) factor’ was fat soluble and found in a range 
of different foods from a variety of cereals to animal organs.  Dam named the factor 
Koagulations vitamin due to its apparent link with clotting. This accessory factor was 
later abbreviated to vitamin K and Dam was awarded the Nobel Prize in 1943 for his 
discovery. 
 
Edward Doisy and his colleagues continued research into this new area and 
succeeded in isolating vitamin K from fish meal by the end of the 1930s.  It was at 
this time that the first clinical trials with administration of vitamin K began 
(9)
. Along 
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with Carl Dam, Edward Doisy shared the Nobel Prize for his discovery of the 
chemical nature of vitamin K.  
 
This extracted fishmeal product was entitled K2 by Doisy and its availability enabled 
others to study the effects of administration of vitamin K to new-born babies 
suffering from haemorrhagic disease 
(7)
. Research in 1937 found that clotting times in 
normal neonates were around 30-60% of adult levels, falling to 15-30% on day two, 
and then gradually rising again until about 10 days following birth. This ‘evidence’ 
that vitamin K deficiency caused Haemorrhagic Disease of the Newborn (HDN), 
along with the newfound ability to synthesise vitamin K, led to various trials to 
ascertain which was the most effective amount and route to use in prophylaxis. By 
the 1950’s, most maternity units had a policy of giving infants oral vitamin K 
immediately after birth 
(10)
. 
 
Classification 
The term ‘vitamin K’ is the name given to all compounds which possess the ability to 
act as a cofactor for the enzyme gamma-glutamylcarboxylase. Vitamin K is 
classified according to its chemical structure, and two forms exist in nature, grouped 
as either phylloquinones (vitamin K1) which are synthesized by green plants and 
which have a phytyl side chain (see figure 1), or menaquinones (vitamin K2) which 
are obtained from animal sources and synthesised by bacteria found in the intestine.  
 
The menaquinone molecules have a tail composed of repeating unsaturated 5-carbon 
(prenyl) units. Further subdivision can be made to menaquinones. Depending on the 
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number of these 5 carbon repeats, they are categorised using the term menaquinone-n 
(MK-n), (n) relating to the number of prenyl units and currently 13 are known to 
exist.      
 
A third form of vitamin K exists, Menadione, which is a synthetic form possessing a 
much simpler structure than the naturally occurring forms however it is unable to 
exert all the functions of naturally occurring vitamin K. Research has focused around 
Menadione’s potential antitumor properties with several in vitro studies identifying 
anticancer activity 
(11)
. 
 
Figure 1 – Structure vitamin K1, vitamin K2 and vitamin K3 taken from 
(12)
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Function 
Vitamin K has been identified as the essential micronutrient needed to enable the 
conversion of glutamate (an amino acid) to gamma-carboxyglutamate (Gla) by post-
translational carboxylation. As previously stated it acts as a cofactor for the enzyme 
gamma-glutamyl carboxylase which oxidizes vitamin K hydroquinone into vitamin 
K epoxide, while simultaneously adding CO2 to protein-bound glutamic acid (Glu) to 
form the  gamma-carboxyglutamic acid (Gla). This carboxylation reaction will only 
occur if the carboxylase enzyme is able to oxidize vitamin K hydroquinone to 
vitamin K epoxide at the same time. Finally vitamin K epoxide is reconverted back 
into vitamin K by vitamin K epoxide reductase (VKOR) - this  process being 
commonly called the ‘vitamin K cycle’ (see figure 2). This recycling of vitamin K 
occurring within the body’s cells is one of the reasons why severe vitamin K 
deficiency is rare as, despite the fact that the body has a limited ability to store 
vitamin K, the cycle allows vitamin K to enable the gamma-carboxylation of proteins 
many times, decreasing the daily dietary requirement. 
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Figure 2:  The ‘vitamin K cycle’ (modified from Stafford, 2005) (13) 
 
 
                                                                                                 Carboxylation 
           Quinone reductase 
 
 
                                                     
 
                                                   VKOR 
 
Warfarin, a commonly used anticoagulant drug, interrupts this cycle by inhibiting 
vitamin K epoxide reductase. If administered in large doses it causes bleeding, and is 
commonly used as a poison for rats due to this property, but when administered at a 
therapeutic dose it can be used to prevent the formation of harmful thrombi, e.g. in 
atrial fibrillation or to treat deep venous thrombosis.  
 
In recent years more than a dozen vitamin K dependent proteins (VKD) have been 
identified (see Table 1) of which all require the presence of γ -carboxyglutamate 
(Gla) residues to function successfully. The enzyme γ -glutamyl carboxylase has 
been found not only in the liver but more recently in other tissue such as skin, lung 
and kidney and this has led researchers to investigate what other functions  the Gla 
proteins may have in the body other than that of blood clotting 
(14)
.  
 
Vitamin K 
expoxide 
Vitamin k 
 
Vitamin K 
hydroquinone 
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Table 1 – Name, site & function of currently identified Gla proteins     
 
Gla proteins - Name Abbreviation Site Function 
Prothrombin FII liver – plasma procoagulant 
Factor VII FVII liver – plasma procoagulant 
Factor IX FIX liver – plasma procoagulant 
Factor X FX liver – plasma procoagulant 
Protein C  liver – plasma anticoagulant 
Protein S  liver – plasma anticoagulant 
Protein Z  liver – plasma anticoagulant 
Osteocalcin OC / BGP bone - dentin regulator of crystallization 
Matrix Gla Protein MGP cartilage & 
arterial  vessel 
wall 
inhibitor of ectopic 
calcification 
Growth arrest specific  
gene-6 protein 
gas6 most soft tissues regulator of cell growth 
(may play a role in vascular 
& ageing nervous system) 
Proline-rich Gla 
proteins 
PRGP most soft tissues Currently unknown 
Transmembrane Gla 
proteins 
TMG3,TMG4, 
PRGP1,PRGP2 
most soft tissues Currently unknown 
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Dietary Sources 
With recent advances in nutritional science such as high performance liquid 
chromatography (HPLC), it is now possible to obtain accurate measurements of 
vitamin K levels in foodstuffs 
(15)
 resulting in the compilation of a national UK 
database for the vitamin K content in food 
(16)
.  For oral intake the most abundant K 
vitamins appear to be the phylloquinones (K1), which are to be found in leafy green 
vegetables such as cabbage and broccoli and contribute up to 40-50% of total intake.  
 
Vitamin K1 can also be found in some plant oils such as soybean and olive oils. 
The naturally occurring menaquinones (MK) collectively known as K2 are found in 
small amounts in meats, eggs and also in fermented foods such as cheese. These 
particular food sources have limited absorption in the large intestine, and so 
contribute to only 10% of the total intake 
(10;11)
, the exception to this being the 
Japanese food natto which is made from fermented soybean and  has a menaquinone 
content which is higher than the phylloquinones to be found in any of the  green 
vegetables.  In healthy adults the large intestine contains bacteria which synthesise 
many of the menaquinones, mainly MK6-MK12 
 
A comparative study using data gathered from the 1986-7 Dietary and Nutritional 
Survey of British Adults and data collected from the 2000-1 National Diet and 
Nutrition Survey compared daily intakes of vitamin K among British adults in both 
1986-7 and 2000-1. Sixty per cent of vitamin K intake as recorded (on 7 day food 
diaries) came from green leafy vegetables, with higher intakes recorded in men than 
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in women. The intake of vitamin K was noted to be considerably lower by 2000- 
2001 mainly  due to a reduction in the consumption of vegetables 
(17)
.  
 
Absorption  
The efficiency of vitamin K absorption depends on the source of the vitamin and 
amount of fat in the diet but, in contrast to other fat soluble vitamins, vitamin K can 
only be stored in the body in limited quantities. Phylloquinones, which are the major 
source of vitamin K in humans, are absorbed in the jejunum and ileum in the 
presence of bile and pancreatic juices. Menaquinones are absorbed in the same 
fashion with the result that patients suffering from fat malabsorption syndromes such 
as those with coeliac disease, cystic fibrosis or Crohn’s disease may develop vitamin 
K deficiency 
(18)
. 
 
Once the phylloquinones have been absorbed they enter the bloodstream and are 
transported chemically unchanged to the liver for utilization and then distributed to 
other body tissues including skeletal, muscle and heart tissue. The liver has only a 
limited capacity for storage of vitamin K and it is the menaquinones which make up 
the majority  (around 90%) of  all stored vitamin K  
(8;19)
.  Compared with other fat-
soluble vitamins, the total body store of vitamin K is small and the turnover of 
vitamin K in the liver is rapid.  Although the liver contains menaquinones, their 
absorption and their contribution to the human vitamin K requirement has not yet 
been fully elucidated. Many hepatic menaquinones are untraceable in plasma. 
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Human requirements     
The overall the amount of dietary intake of vitamin K the body requires is  relatively 
low in relation to other  nutrients 
(20)
. The current Adequate Intake (amount of 
nutrient required by the body to reduce the risk of developing associated diseases) of 
vitamin K, as taken from the Third Health and Nutrition Examination Survey 
(NHANES III) 1984 – 1994 has been set at 120µg/d for men and 90µg/d for women 
(equivalent to eating 3 to 4 brussel sprouts or two to three spears of broccoli per day). 
Debate over this recommendation exists however with 1 µg/kg/day currently taken as 
the standardised guideline set by the UK  Department of Health in 1991 while the 
World Health Organisation (WHO) currently recommends a daily intake of vitamin 
K 60–90 µg/day as adequate for older persons (21).The Framingham  cohort study 
reported that individuals who fell into the category of high intake of vitamin K 
(median 254 µg/d) as recorded on food record diaries had a significantly lower risk 
of hip fracture than those in the  lowest intake group (median 56 µg/d) 
(22)
. The UK 
National Diet and Nutrition survey identified that the average intake of older people 
was between 80–120  µg/d while studies of younger populations found average 
intake to be around 60–70 µg/d  with similar figures obtained in population based 
surveys in the USA 
(23)
. 
 
Experiments carried out on laboratory animals have shown that vitamin K has a short 
half-life of only a few days, but despite this the intake in healthy adults appears 
sufficient to ensure normal blood clotting; in part ensured because of the efficient 
way the liver extracts and accumulates the vitamin. 
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Current recommended figures are based purely on the requirement for vitamin K in 
blood clotting and do not take into consideration recent understanding of its role in 
both bone and vascular health, hence deficiency has to date been defined as “a state 
in which undercarboxylated blood coagulation factors appear in the circulation” (24). 
 
There are currently 3 forms of supplementation available: vitamin K1; synthetic 
vitamin K2 MK-4; and natural vitamin K2 MK-7 (menaquinone-7). Previous vitamin 
K comparison studies exist. One such study involving healthy volunteers assessed 
the pharmacokinetics of both vitamin K1 and vitamin K2 with  both peaking at around 
4 hours following ingestion  but, while the vitamin K1 serum levels displayed only a 
short half-life time of  1-2 hours,  vitamin K2 had a much longer half-life of 3 days 
resulting in more stable serum levels 
(25)
.  Observational studies also suggest that it is 
in fact vitamin K2 and not vitamin K1 which is associated with a lower incidence of 
cardiovascular events 
(26)
 and thus vitamin K2 was the choice of intervention for this 
particular study.  
 
Toxicity 
European legislation exists defining vitamin and mineral supplement intake and 
upper levels have been set by the European Food Safety Authority (EFSA) or the 
Scientific Committee for Food (SCF). Research carried out in 1940 on laboratory rats 
saw dosage of up to 25g/kg of vitamin K administered without any adverse effect 
(27)
 
and there has been no known toxicity or adverse effects in healthy individuals 
associated with intake in excess of the recommended dose. In common with vitamin 
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B2, vitamin B1 and vitamin B12, no tolerable upper level of intake of vitamin K has 
been established 
(28)
. 
 
Measurement of vitamin K status 
Serum vitamin K level can be measured by High Performance Liquid  
Chromatography (HPLC), with the normal range of plasma vitamin K in adults aged 
65 to 92 years being 0.32 to 2.67ng/mL 
(29)
. Levels below 0.5 ng/mL have been 
linked to impaired blood-clotting. The value of measuring serum vitamin K 
concentration to assess vitamin K status is limited because it reacts to changes in oral  
intake within a 24 period as noted in a study of pre and post-operative surgical 
patients 
(30)
.   
 
Vitamin K deficiency results in impaired blood clotting, which can be confirmed by 
laboratory tests which measure the concentration of the vitamin K dependent factors. 
Prothrombin Time (PT) specifically evaluates the presence of factors VII, V, and X, 
prothrombin and fibrinogen in the blood with the normal range in a healthy 
individual being 11 - 13.5 seconds. More recently other methods for assessing 
vitamin K status have been developed including the measurement of 
undercarboxylated prothrombin and undercarboxylated osteocalcin. 
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Role of Vitamin K in Disease Processes 
Role of Vitamin K in Clotting                  
Vitamin K is required for the process of coagulation in blood clotting 
(31;32)
, with the 
vitamin K dependent proteins being identified as: Prothrombin;  Factor VII; Factor 
IX; Factor X; Protein C; Protein S and Protein Z.                                       
 
Haemostasis 
When damage occurs to blood vessels the homeostatic process is triggered. This 
consisting of 3 mechanisms which work together to stop the flow of blood. Firstly 
vasoconstriction of the damaged vessel slows the blood flow while the second 
mechanism of platelet adhesion to plug the wound occurs. Coagulation (the third 
mechanism in the process) then occurs as a result of activation of the ‘coagulation 
cascade’ – a process where a series of events, which are all interdependent, stop 
bleeding by the formation of a clot.   Damage to tissue outside the vessel starts a 
release of  the Gla protein factor III, which with the aid of calcium activates factor 
VII, which initiates the ‘extrinsic pathway’ (see below). At the same time, the Gla 
protein Factor XII from active platelets will activate factor XI, initiating the intrinsic 
pathway. Both active factor VII and active factor XI promote cascade reactions, 
eventually triggering the Gla protein factor X. Active factor X, along with factor III, 
factor V, Calcium and platelet thromboplastic factor (PF3), activate prothrombin 
activator which converts prothrombin to thrombin. Thrombin converts fibrinogen to 
fibrin which  initially forms a loose web with factor XIII causing the formation of 
cross links; this much denser structure of fibres ensure that  platelets and red blood 
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cells become caught in this mesh resulting in the formation of a blood clot (see 
Figure 3).       
 
Figure 3: Diagram of the clotting cascade reproduced from 
(33)
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Two other vitamin K dependent proteins, protein C and protein S, play a regulatory 
role in clotting by inhibiting coagulation via the inactivation of Factors V and VIII. 
Protein C circulates in the blood as a zymogen and is activated to a serine protease 
  
 34 
by the binding of thrombin to thrombomodulin, while protein S enhances the action 
of Protein C.  By deactivating Factors V and VII, Proteins C and S decrease the 
speed of thrombin production, thereby inhibiting the cascade and acting as the 
regulatory mechanism of the clotting cascade. Without this mechanism, widespread 
thrombosis would otherwise occur.  There is evidence that protein S is synthesized 
by several tissues including bone and blood vessels and may have other functions 
besides its role as an inhibitor of clotting. The other vitamin K-dependent protein 
(protein Z) is assumed to have a haemostatic role but as yet its function is unclear. 
 
Role of Vitamin K in Bone health                   
Osteoporosis is one of the most common disorders associated with old age, affecting 
one in every three women and one in every twelve men over the age of 50 years. 
Reduced bone density is a major risk factor for low trauma fracture, with consequent 
disability, death and cost to society 
(34)
.  Osteoporosis has been defined as “a 
progressive, systematic, skeletal disease that is characterised by low bone mass and 
deterioration of the small structures in the bones with subsequent increase in bone 
fragility and susceptibility to fracture” (35), and more recently osteoporosis has been 
operationally defined on the basis of bone mineral density (BMD) assessment. 
According to the WHO criteria, osteoporosis is defined as a BMD that lies 2.5 
standard deviations or more below the average value for young healthy women 
(36)
. 
 
Although the role of calcium in bone health has long been established, other 
nutritional deficiencies may also play an important part in bone loss 
(37)
. Bone matrix 
is formed by osteoblasts which synthesize osteocalcin, and vitamin K has been 
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identified as necessary to enable gamma glutanyl carboxylation of osteocalcin.  
Without this post translational modification osteocalcin is inactive and the body 
cannot mineralise bone effectively. Serum levels of under carboxylated osteocalcin 
levels can therefore be used to measure the effect of vitamin K intake on bone health. 
 
Over the past few years accumulating evidence supports a role for vitamin K in bone 
health. In the majority of studies higher intake of phylloquinones is associated with 
lower serum concentrations of undercarboxylated osteocalcin. This in turn has been 
associated with lower bone mineral density and a higher  risk of hip fracture 
(38;39)
.  
 
The direct relationship between phylloquinone intake and bone mineral density has 
also been reported although this appears less consistent. The ECKO study 
randomised 440 postmenopausal women to receive either 5mg vitamin K1 or placebo 
for a minimum of 2 years. Despite showing a 10 fold increase in serum K1 levels 
along with a decrease in the  proportion of undercarboxylated osteocalcin levels no 
improvement in age related BMD was found 
(40)
. The Framingham observational 
study investigated vitamin K intake in older women (mean age 75 years) with a mean 
vitamin K1 intake of 155µg/ day.  While it found no correlation between vitamin K 
intake and either bone mineral density or bone loss, in the Framingham offspring 
cohort a positive correlation was found in younger women (average age 59 years) but 
not men 
(41)
. The Nurses’ Health Study followed 120,000, women for a period of 10 
years and a prospective analysis of this cohort discovered that the women with the 
lowest risk of hip fracture were those middle aged and older women who reported 
higher levels of vitamin K consumption on their food questionnaires 
(39)
. 
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An epidemiological study of Japanese premenopausal women compared those who 
traditionally have a high intake of vitamin K (MK7) ingested as fermented soybean 
with women from another Japanese area with a staple diet and British women whose 
diet did not include natto.  Those Japanese women consuming the natto (soybean) 
showed  significantly higher  serum levels of circulating MK7  and researchers found 
a statistically significant inverse correlation between natto consumption and the 
incidence of osteoporotic hip fracture 
(42)
.         
 
Role of Vitamin K in Vascular Disease 
One of the cardinal signs of cardiovascular disease is the formation of atherosclerotic 
plaques in arterial walls. Until recently calcification of arteries was thought to be a 
passive and clinically irrelevant process, a result of inflammation, lipid 
accumulation, diabetes or high calcium. However it is now clear that vascular 
calcification is in fact an active, structured process which is strongly and 
independently associated with an increased risk of cardiovascular morbidity and 
mortality. Calcification results in reduced elasticity (stiffening) of the vascular walls 
causing a reduction of arterial compliance, which promotes development of left 
ventricular hypertrophy and causes decreased coronary perfusion. The end result is 
an increased risk of serious complications – myocardial infarction, stroke, heart 
failure and cardiovascular death. 
 
In the vasculature a key inhibitor of calcification is the Gla protein Matrix Gla 
protein (MGP) which is synthesised by smooth muscle cells and is found in a wide 
variety of tissues including cartilage, heart, kidney and lung. 
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The role of vitamin K in vascular calcification was proposed over 30 years ago when 
a study of vitamin K dependent proteins in aortic valve calcification found evidence 
of Gla in all the calcified valves studied while those valves without calcification had 
no traceable Gla 
(43)
. Within vascular smooth muscle cells the synthesis of MGP 
prevents vascular calcification as shown in studies of mice where the removal of the 
MGP gene resulted in calcification of the elastic lamellae of the abdominal aorta with 
death from rupture of the aorta occurring within two months 
(44)
. Other studies found 
that rats who were given the vitamin K antagonist warfarin developed vascular 
calcification after 2 weeks  
(45)
 while in humans uncarboxylated MGP (i.e. non-
functional MGP) has been identified in calcified regions of the vasculature 
(38)
.   
 
The link with atherosclerosis was first considered when proteins containing Gla 
residues (osteocalcin and MGP) were isolated from atherosclerotic plaques. A 
population based study with 113 post-menopausal women found a link between low 
levels of vitamin K and atherosclerotic calcification in the abdominal aorta 
(46)
.  
Apparently healthy people have shown substantial under carboxylated MGP 
suggesting that these healthy adults may be vitamin K deficient 
(47)
. It has thus been 
suggested that previously identified Recommended Daily Intake levels for vitamin K, 
although sufficiently high to maintain a regulated clotting mechanism may not be 
high enough to ensure the complete carboxylation of all the other vitamin K 
dependent proteins required to maintain healthy bone and artery wall function.  
Importantly a review of current literature showed no evidence for intake of vitamin 
K1 but interestingly 2 cohort studies have found an association between vitamin K2 
and fewer CHD events 
(38;48)
, while a study  of 118 postmenopausal women, assessed 
 38 
the effect of supplementing the diet with vitamin K, vitamin E and calcium and 
found this had a beneficial effect on elasticity and compliance of the carotid artery 
when compared  to other groups without vitamin K supplementation 
(49)
 . 
 
A recently completed randomised controlled trial confirmed that most patients 
requiring haemodialysis have a deficiency in vitamin K. It also demonstrated that 
daily supplementation with vitamin K decreases the levels of inactive MGP 
providing strong evidence to proceed to a full study looking at the effect on vascular 
calcification in this high risk group 
(50)
. 
 
1.3 Population Ageing 
Ageing, as defined by Kirkwood, is “the progressive loss of function accompanied 
by decreasing fertility and increasing mortality with advancing age” (51). The WHO 
2008 classes those over the age of 70 years as being ‘elderly’, those 75-89 years as 
‘old’ and those over the age of 90 years being ‘very old’ (52). In almost every country 
in the world, the proportion of people aged over 60 years is growing faster than any 
other age group. It has been projected that by 2035 23% of the UK population will be 
aged ≥65 years with 3.6 million being aged ≥85 years (19).   
 
In the early twentieth century better hygiene, public health, nutrition and better 
obstetric care resulted in a rapid decline in the mortality of the population of 
developed countries around the world 
(53)
. This trend along with declining fertility 
rates has given rise to a reduction in the number of young persons under the age of 
15 years but an increase in the population of those in the later stages of life. As a 
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result “population ageing” - the process by which older individuals make up a 
proportionally larger share of the total population over a period of time - has thrown 
up new challenges to both developed and developing countries such as the increasing 
demand and expense on healthcare and social care.             
 
WHO currently records the world’s total population of those aged 60 and above at 
650 million but it expects this figure to reach 2 billion by 2050. According to the 
Office for National Statistics (ONS) in Scotland the number of people of pensionable 
age is expected to rise by 3% from 1.04 million in 2010 to 1.07 million in 2020 and 
then reach 1.32 million in 2035, while the number of people aged 75 and over is 
anticipated to increase from 0.41 million in 2010 to 0.50 million in 2020 and to 
continue rising, reaching 0.74 million in 2035 – an increase of 82 per cent over the 
25 year period.                           
 
Age Structure  
Within Scotland there has been very little change in the total number of people over 
the past 50 years, but the age profile of the population has changed quite significantly 
within the past decade 
(54)
. One hundred years ago there were few older people and a 
large, young, working age population to support them; average life expectancy was 
only 40 years. However it is predicted that by 2031 in Scotland the number of people 
aged 65 years or over will increase from 0.75 million in 2000 to 1.2 million in 2031. 
(See figure 4.) Those who are aged ≥65 will have increased by 62% while those aged 
≥85 will have increased by 144%.  The population of older persons is itself ageing. 
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Among those aged 60 years or over, the fastest growing population is that of the 
oldest-old, that is, those aged 80 years or over. 
 
Figure 4 - Population pyramids of Scotland by age group and sex (1911, 1951, 
1991 and 2031) taken from National Workforce Planning Framework 2005 
(55)
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While population ageing is a success story for public health policies and for 
socioeconomic development, it brings with it many challenges for both individuals 
and for society as a whole.  As the proportion of older people increases, so the age 
structure of Scotland’s population is also changing (see figure 5). By 2010 there were 
more people aged 65 years and over (20%) than there were under the age of 16 
(17%). 
 
Figure 5: The changing age structure of Scotland's population, 2000-2010 taken 
from 
(56)
 
 
 
Life Expectancy 
UK life expectancy at birth is 78 years for males and 82 years for females 
(57)
. Old 
age is however associated with health problems including chronic diseases such as 
hypertension, diabetes mellitus, coronary artery disease, stroke, dementia and chronic 
obstructive pulmonary disease (COPD) with  chronic disease being  closely linked to 
a reduced quality of life 
(58)
. 
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While life expectancy is defined as the expected number of years of life remaining at 
a given age, healthy life expectancy (HLE) is defined as the period of life one can 
expect to spend in good health and is currently calculated by the recording of self-
reported overall general health status. Health expectancies can be measured in 
several ways, including life expectancy in good health, free from disability, or free 
from a specific disease. While data suggests a rise in both life expectancy and 
general HLE between 1981 and 2001 there has been a slight drop in the reported % 
of life spent in good health with women reporting more chronic ill health and 
disability than men 
(59)
. (See Table 2.)  
 
Table 2:Trends in life expectancy and healthy life expectancy at birth, 1981 to 2001 
(source www.statistics.gov.uk) 
 Women Men 
Year 1981 2001 1981 2001 
Life expectancy (years) 76.8 80.4 70.9 75.7 
General HLE (years) 66.7 68.8 64.4 67.0 
% life in Good or fairly good health 86.9% 85.6% 90.0% 88.5% 
HLE: - Healthy Life Expectancy 
 
Observational data show that while for both male and females’ life expectancy at 
birth for the UK as a whole continues to rise and the gap between males and females 
is also closing, men and women in Scotland have some of the lowest life expectancy 
at birth in the European Union (EU). For males, life expectancy at birth is almost one 
year lower than the EU average and, for females; it is almost two years lower. For 
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both sexes, life expectancy is about four years lower than those countries with the 
highest life expectancy. 
 
HLE without disability is also lower in the UK compared to the average within the 
EU (see figure 6.  UK figures from 2005 show while men aged 65 can expect to live 
another 10 years without disability they should expect to spend their last 7 years with 
one. Women at 65 years are likely to live a further 12 years without followed by 9 
years with a disability. This constitutes a total of 43% of their remaining life span at 
65 years spent with some form of disability.  
 
Figure 6: Expected healthy life years remaining for people aged 65 throughout 
European countries in  2005  
(60)
. 
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Mortality 
In previous centuries death was frequently the result of outbreaks or epidemics of 
infectious diseases. Improved sanitary conditions, better nutrition, antibiotics and 
immunisations have now left the developed countries of the world with new 
epidemics to deal with.  
 
In Scotland mortality rates from the big three killers - cancer, coronary heart disease 
and stroke - account for more than 50% of deaths recorded in Scotland, with 15% 
being attributed to coronary heart disease and 9% to stroke in 2010. The past two 
decades however have seen these rates steadily decline (see Figure 7) partly as a 
result of health education, lifestyle improvements and improved health care 
interventions. In 2005, 60% of deaths were of people aged 75 and over, and a further 
20% occurred in those who were between the ages of 65 and 74. The relative 
stability of the number of deaths over recent years masks significant improvements 
in age-specific mortality. The consequence of this is that there are ever more older 
people surviving with chronic cardiovascular diseases. 
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Figure 7 Scotland’s Population - Mortality Rates (61) 
 
 
1.4   Cardiovascular Disease in Older adults 
For many people old age is associated with ill health. Although death rates have been 
falling, cardiovascular disease remains the biggest cause of death in the UK 
accounting for 1 in 3 of all recorded deaths and currently costing the UK economy 
around £30 billion per year 
(62)
. Given that chronic disease reflects a lifetime 
exposure to damaging risk factors, most chronic conditions will manifest themselves 
in later life and are as a result of multiple disease processes.  
 
Mortality rates in Scotland from cardiovascular disease are among the highest in the 
world. It is the main cause of death in the UK annually accounting for 191,000 or 
one in three of all deaths and, while there has been a dramatic reduction in death 
rates, its prevention remains high on the Scottish Government’s agenda. Once an 
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individual reaches the age of 65 their risk of developing cardiovascular disease 
increases, and cardiac-related disease accounts for around 40% of deaths in the 65 to 
74 year age group 
(63)
. In 2009 of the 180,000 recorded deaths only 25,000 were 
under 75 years. Not only is it a major cause of mortality but it is also a major 
contributor to the decline in physical function in old age 
(64)
. 
 
Current knowledge about the management of cardiovascular disease, especially in 
relation to drug treatments, has in the main been taken from studies carried out in 
younger populations 
(65)
,  despite the aforementioned physiological differences and 
the increased likelihood of co-morbid disease. Lifestyle factors such as diet and 
physical activity are important contributors to the prevention and treatment of 
cardiovascular diseases, and there is evidence to support improvements with disease 
following short periods of intervention (e.g. stopping smoking and taking exercise). 
While much nutritional research has focused on fat and salt intake, there is growing 
interest in the role of micronutrients in the prevention of chronic disease. 
 
In early life arteries are elastic and flexible, which facilitates optimal cardiac 
function. With advancing age however a gradual thickening of the arteries’ muscle 
layer (the tunica media) along with an increase in the deposition of collagen fibres 
and elastin becomes apparent, while other substances involved in inflammatory and 
atherosclerotic reactions are also more plentiful in older arteries 
(66)
.  Arterial 
stiffness increases primarily due to a breakdown of the elastin fibrous structure of the 
arterial walls but also due to an increase in mean arterial pressure. 
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Vascular calcification is common in the older population as well as in those suffering 
from chronic kidney disease, diabetes and aortic stenosis. Studies using animals have 
shown that it is possible to reverse calcification of the arteries but two human studies 
using intensive lipid-lowering therapy have not proved successful in preventing the 
progression of coronary calcification 
(67;68)
  
 
Hypertension 
Cardiovascular diseases are the leading cause of death worldwide, with high blood 
pressure causing 7 million deaths each year 
(69)
.Blood pressure is recorded as 
systolic/diastolic blood pressure measured in millimetres of mercury (mmHg).  
Raised blood pressure is diagnosed when either the systolic pressure exceeds 
140mmHg or the diastolic exceeds 90mmHg with hypertension being the recording 
of raised blood pressure on three subsequent occasions 
(70)
.  In Scotland one third of 
all the adult population has high blood pressure the prevalence of which increases 
with age such that more than two thirds of the Scottish population aged over 75 have 
high blood pressure 
(71;72)
.  
 
Hypertension is known to accelerate arthrosclerosis, increasing the risk of vascular 
disease, and may result in coronary heart disease, left ventricular hypertrophy, 
transient ischaemic attack and peripheral vascular disease (PVD) 
(73) 
with  the 
Framington study demonstrating the link between hypertension and cardiovascular 
disease (CVD) as well as hypertension and left ventricular mass 
(74)
. Furthermore, in 
older patients there is a link between arterial stiffness and high blood pressure 
 48 
especially in those with ischemic heart disease. These patients are therefore an ideal 
group to target for testing the effect of vitamin K on artery function. 
 
Diabetes Mellitus 
Diabetes mellitus is a metabolic disorder characterised by chronic hyperglycaemia 
resulting from defects in insulin secretion and glucose disposal. Recent figures 
indicate that one person in every 25 in Scotland has been diagnosed with the 
condition, and that level is increasing at a rate of 4% per year 
(75)
.  
 
Diabetes mellitus and CVD share several characteristics. Both increase in incidence 
with age, are associated with lifestyle factors, and both may be reduced if common 
risk factors are reduced 
(76)
. Diabetes has been identified as a risk factor for CVD, 
with coronary heart disease the most common vascular complication among people 
with diabetes, resulting in an increased risk of cardiovascular morbidity and 
mortality. The Framingham Study found that the incidence of CVD among diabetic 
men was double that found in non-diabetic men, while in the female population 
cardiovascular disease was found to be three times more common in those with a 
diagnosis of diabetes 
(77)
.  
 
Diabetes is also closely linked to other risk factors for CVD; hypertension 
(78)
 and 
dyslipidaemia 
(79)
 are significantly more prevalent in this population, with the risk of 
stroke within the first 5 years of diagnosis found to be double that of the general 
population in a population-based cohort study (80). Medial calcification is also found 
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to be more prevalent in those with diabetes mellitus thus this group of patients are an 
ideal group to target for testing the effect of vitamin K. 
 
Established Vascular Disease 
For those with established vascular disease such as myocardial infarction, stroke or 
peripheral vascular disease, the risk of having a second event is higher than in those 
groups without such history.  
 
Those with established vascular disease are more likely to have impaired endothelial 
function and stiff arteries, and are therefore potential targets for improvement with an 
intervention. 
 
Thus vascular disease is a common, important contributor to disease in old age. 
There now exists a body of evidence to suggest that vitamin K may be able to modify 
vascular disease, but to test this hypothesis, randomised controlled trials are needed. 
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2. METHODS 
2.1 Study Aims 
The aims of the study were:  
1. To determine whether supplementation with vitamin K improves markers of 
vascular health in older people with existing vascular disease.  
2. To determine whether vitamin K supplementation improves physical function in 
older people with existing vascular disease.  
 
2.2 Study Design 
The study was a parallel group, double blind, placebo controlled, randomised trial. 
The study was approved by Tayside Committee on Medical Research Ethics (ref 
number 11/009) on 12
th
 September 2011 and was funded by Chest, Heart & Stroke 
Scotland (reference R11/A137). 
 
 2.3 Sample Size 
The primary outcome was a change in flow-mediated dilatation of the brachial artery 
between baseline and 6 months. In anticipation of a 10% dropout rate (based on 
previous trials 
(81;82)
) a final sample size of 80 (40 per arm) would give 80% power at 
alpha = 0.05 to detect a 2% absolute change in FMD (given a standard deviation of 
change of 3% as seen in previous studies 
(81)
).  
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2.4 Study Population 
Community dwelling people aged 70 and over with a history of hypertension, 
diabetes or previously diagnosed vascular disease (see Table 3 for inclusion and 
exclusion criteria) were recruited from the community via the Scottish Primary Care 
Research Network (SPCRN). This group of patients has a high risk of recurrent 
vascular events and therefore would have most to gain from any effective 
intervention.  
 
Exclusion Criteria 
A minimal exclusion criterion for the study was set to ensure the presence of as wide 
a range of older people with vascular disease as possible. Given that warfarin inhibits 
vitamin K epoxide reductase those prescribed warfarin or those with a diagnosis of 
atrial fibrillation and therefore potentially requiring warfarin treatment in the future, 
were not included in the study population or indeed those who stated that they 
already supplemented their diet with vitamin K supplements. 
 
Anyone unable to give informed consent or unable to walk without physical 
assistance, and thus unable to participate in the physical functioning assessment, 
were also excluded 
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Table 3. Inclusion and exclusion criteria 
 
 
 
 
 
 
 
 
 
 
Inclusion criteria   
 Age 70 and over with at least one of the following diagnosis: 
 Hypertension (based on recorded diagnosis from primary or secondary care) 
 Diabetes mellitus (based on recorded diagnosis from primary or secondary 
care) 
 Established Vascular disease – one or more of:  
1. Myocardial infarction (based on symptoms of ischaemia or ECG 
changes, plus rise in cardiac enzymes)  
2. Percutaneous transluminal coronary angioplasty 
3. Coronary artery bypass grafting 
4. Stroke/TIA (based on a recorded diagnosis established in secondary 
care and recorded in the medical case notes) 
5. Peripheral vascular disease (symptoms of peripheral ischaemia and 
either a previous ankle/brachial pressure index <0.7 OR  
6. Previous evidence of arterial stenosis on angiography or ultrasound) 
Exclusion criteria  
 Atrial fibrillation 
 Taking Warfarin 
 Taking Vitamin K supplements  
 Unable to give written informed consent 
 Unable to walk without human assistance (walking aids are permitted) 
 Participation in another study 
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2.5 Investigator Training 
The investigator (RF) undertook a period of training prior to recruitment of 
participants to the study. Good Clinical Practice training was undertaken at the 
Clinical Research Centre (see appendix 1) with all other training was carried out 
within the department of medicine at Ninewells Hospital and encompassed both 
instruction in the vascular assessments and the physical function tests. 
Training began with repeated demonstration of the techniques by an experienced 
practitioner, which gave the investigator the opportunity to observe formally the 
techniques being carried out successfully. All training manuals and standard 
operating procedures were read until RF had a full and clear understanding of the 
procedures. 
In order to assess reproducibility, Flow Mediated Dilation (FMD), carotid intima-
media thickness and pulse wave velocity (PVW) were carried out on 20 individuals 
initially under close supervision before being repeated at least 3 times on each 
volunteer. For FMD measurements are taken pre and post forearm artery occlusion 
with the increase expressed as percentage change from baseline. An absolute 
percentage change of 2% is considered to be clinically significant therefore an 
increase of less than 2% was considered satisfactory to demonstrate reproducibility. 
Regular meetings with the experienced practitioner where held to allow results to be 
studied.  Tables (4&5) below show FMD and PWV results on the final ten healthy 
 54 
volunteers and demonstrate that techniques where being reproduced to an acceptable 
level and recruitment of participants could begin. 
 
Table 4. Training records for FMD healthy volunteers 
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Table 5. Training records PVW healthy volunteers 
 
 
2.6 Participant Selection and Enrolment 
Recruitment 
Participants were recruited through SPCRN, previously known as the Scottish 
Practices and Professionals Involved in Research (SPPIRe). The network, which was 
established in 2002, aims to act as a framework to co-ordinate national research 
activity in primary care. It is funded by the Chief Scientist Office of the Scottish 
Government and is operationally managed at a regional level by four nodes based in 
the North, East, South East and West of Scotland. 
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Participants were recruited using the East of Scotland node of the SPCRN. GP 
practices who are members of the network were sent information regarding the study 
and two practices who agreed to be involved in the research project were visited by a 
SPCRN research officer. Using the practice’s patient computer database system and 
the study inclusion / exclusion criteria the research officer produced a list of 
participants who were potentially eligible for the study. The list was then reviewed 
by one of the practice GP’s to exclude any patients who they deemed unsuitable to 
enter the study because, for example, they had recently been diagnosed with a serious 
illness, or had been recently bereaved.  
 
An invitation letter along with a Participant Information Sheet (PIS) (Appendices 2 
and 3), reply slip (appendix 4) and a stamped addressed envelope were sent from the 
GP to the patients who met the study eligibility criteria. After reading the PIS only 
those individuals who wished to know more about the study were asked to respond 
by returning the reply slip. 
Reply slips were collected by the SPCRN team and forwarded to members of the 
study team. Respondents were contacted by telephone by Roberta Fulton (RF). 
During this initial contact a brief outline was given of the purpose of the study and 
details of what involvement in the study would entail. Eligibility was also checked 
and potential participants were encouraged to ask questions at any point during the 
phone call. 
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Informed Consent 
Verbal consent 
All those who agreed to participate in the study and attend the screening / baseline 
visit gave verbal consent during the initial telephone contact for RF to review their 
hospital notes to further assess eligibility and document past medical history.  
 
Written Consent 
Based on the principles of the Declaration of Helsinki, written informed consent was 
obtained from each participant when they attended their screening / baseline visit 
(see appendix 5 for consent form) 
 
Randomisation 
Randomisation of study medication was carried out by Tayside Pharmaceuticals, an 
MHRA licensed manufacturing unit at Ninewells Hospital.  Staff at Tayside 
Pharmaceuticals prepared and retained a computer-generated randomisation list 
randomised on a 1:1 ratio (active: placebo) with no stratification. Four blocks of 20 
participants were randomised to ensure equal allocation across both arms of the trial, 
even in the event of suboptimal recruitment.  
 
On entering the study each participant was allocated a sequential number and was 
dispensed the study medication bearing the same number, each bottle containing 
medication sufficient to last for 6 months.  
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Each participant was dispensed an identical looking bottle informing them that the 
bottle contained either vitamin K or placebo medication ensuring that the participant 
remained blind to the study medication. Randomisation codes were held by the 
pharmacy and not by the researchers themselves; however the codes were held in a 
sealed enveloped in the trial master file (TMF) in case emergency unblinding was 
required out with pharmacy times.   
 
Researchers also remained blind to the treatment allocation which was only broken 
once all the data analysis was complete.  
 
2.7 Medication 
Manufacture 
Study medication was manufactured by NattoPhama ASA (Høvik, Norway) and 
encapsulated by Legosan AB, Kumla, Sweden as vitamin K2 using bacillus subtilis 
natto, a Japanese dish made of fermented soybeans which is currently the richest 
known source of natural vitamin K2 
(83)
.  Participants were randomised to receive one 
capsule per day of either vitamin K2 (MK7 subtype) 100mcg or placebo, with both 
intervention and placebo medications being over capsulated to give an identical 
appearance. All study medication was issued at the end of the baseline visit with 
instructions to take one tablet per day. Participants were instructed to contact RF 
with any questions concerning the medication during their time in the study. 
 
A letter was sent to each participant’s general practitioner notifying the doctor that 
their patient had enrolled in the study and was therefore possibly taking vitamin K 
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(see appendix 6), something which they should be conscious of if they were to 
consider warfarin therapy over the course of the subsequent six months, as vitamin K 
antagonises the effect of warfarin 
(84)
.  
 
Medication Adherence 
Medication adherence, defined by the WHO as ‘the extent to which a patient follows 
medical instructions’, was assessed by a tablet count at 12 weeks and 6 months 
following the participant’s baseline visit. The number of remaining tablets was 
recorded in the case report form (see appendix 7) as was the total number of days 
each participant had been enrolled in the study. Adherence was calculated as the 
proportion of tablets actually taken over the 6 month period divided by the amount 
they should have taken. An intake of 80% or more of the initial tablets supplied at 
baseline was recorded as medication adherent.   
 
Measurements of serum vitamin K levels were also recorded at baseline and at the 6 
month study visits as a further check that medication was being ingested as opposed 
to merely being removed from the bottle. 
All unused medication was recorded on the medication accountability log before 
being returned to the clinical trials pharmacist at Tayside Pharmaceuticals for safe 
disposal.   
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2.8 Outcome Measurement 
Screening Assessment 
All visits for the study were carried out in study rooms at Tayside Institute for 
Cardiac Research, level 7 Ninewells Hospital. Taxi transport was provided if 
required. Assessment of suitability for study entry was reviewed at the screening / 
baseline visit. Inclusion / exclusion criteria were re-examined, and during the initial 
part of the screening / baseline visit a 12-lead electrocardiogram (ECG) was carried 
out. Any patient displaying a recording of atrial fibrillation (AF), a heart condition 
that causes an irregular and often abnormally fast heart rate, on the ECG was then 
excluded from further participation. A copy of the ECG was forwarded on to the GP 
for antithrombotic prophylaxis consideration as people with AF have a five-fold 
increase in risk of stroke and previous trials have established sound evidence to 
support warfarin treatment in high risk groups 
(85)
. It is well documented that vitamin 
K alters the metabolism of warfarin,
(86) 
hence patients in AF were excluded from the 
trial.  The procedure for recording the ECG was carried out as described by Jevon 
(87)
.  Any person with AF on their ECG was gently informed that this is a relatively 
common condition affecting around 20% of the population over the age of 80 years 
(88)
 which can be managed effectively, and that their GP would be informed of the 
findings for further consideration.  
Following consent those participants eligible for inclusion continued with the 
baseline visit as follows: 
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Baseline Assessment 
 Past medical history including dates of diagnosis (if known) 
and whether the condition was currently an on-going problem. 
 Concomitant medications were recorded 
 Demographic information was documented - specifically:   
(i) Current living status (own home, sheltered housing, residential 
or nursing home resident or living with relatives) 
(ii) Living alone at home and current home help  
(iii) Smoking history; current smoking habit  
(iv) Use of walking aids (none, 1 or 2 sticks, zimmer frame or 
triwheel walker). 
 
Lying and standing blood pressure was recorded using an Omron digital blood 
pressure monitor model HEM-400C as per The British Hypertension 
Society/European Society for Hypertension guidelines 
(89)
.  Participants were asked 
to lie in a supine position for 5 minutes prior to the blood pressure being recorded 
three times then asked to stand in an upright position while recordings were taken 
again at 30 seconds, 2 minutes and 3 minutes to test for orthostatic hypotension. 
Participants were asked if they had experienced any feelings of dizziness or light-
headedness during the procedure and these were also recorded in the Case Report 
Form (CRF). Lying and standing blood pressure recordings were documented in the 
CRF, then mean lying blood pressure was also calculated and recorded in the CRF.  
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A falls history was also taken at this time at each of the three study visits, with the 
number of falls occurring within the previous three month period documented along 
with the circumstances surrounding each event. 
 
Primary Outcome Measure 
The primary outcome for the trial was between group differences in endothelial 
function at 6 months as assessed using the technique of Flow Mediated Dilation 
(FMD) of the brachial artery in response to 5 minutes of forearm occlusion. 
 
The endothelium is the largest organ in the body located between the wall of blood 
vessels and the blood stream. Stimuli such as pressure, shear stress, or  hormonal 
stimuli, induce the release substances which regulate vasomotor function, activate 
inflammatory processes, and affect haemostasis 
(90).
  
 
Endothelial dysfunction was first described in human hypertension in the forearm 
vasculature in 1990 
(91)
 and encompasses various abnormalities such as reduced 
vasodilation, altered inflammatory and anticoagulant properties as well as abnormal 
vascular growth remodelling. 
(92)
  It has been demonstrated to be present in patients 
with diabetes 
(93;94)
; hypertension 
(95)
; coronary artery disease 
(96)
; and peripheral 
vascular disease 
(97)
 and is associated with ageing 
(98)
.  
 
The ability of the blood vessels to dilate in response to an increase in blood flow has 
been named FMD and is largely mediated by nitric oxide (NO). This increase in 
blood flow can be produced by triggering reactive hyperaemia (RH), that is, by 
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temporarily occluding an artery and then restoring the flow of blood.  When blood 
flow through an arterial section is occluded, hypoxia causes vasodilation of 
downstream resistance vessels followed by an increase in blood flow upon release of 
the occlusion.  This increase of blood flow increases the shear stress exerted on the 
endothelium initiating release of NO and the relaxation of vascular smooth muscle 
cells. The result is conduit vessel dilation. RH therefore produces a compensatory 
increase in blood flow inducing the release of NO from the endothelium and thus, 
when this technique is carried out under controlled conditions, the impact of  NO 
bioavailability can be measured 
(99)
. The size of the blood vessel, participants’ age 
and gender, as well therapeutic interventions are also known to influence FMD 
(100)
 
as are ambient  temperature and food ingestion 
(101)
. 
 
 
FMD of the brachial artery as devised by Celermajer et al 
(102)
 is a non-invasive, 
reproducible  technique used to assess endothelial function and has been identified as 
a marker for future cardiovascular events in patients with diabetes mellitus 
(103)
; 
essential hypertension 
(104)
; chest pain 
(105)
; peripheral vascular disease 
(106)
 and 
chronic heart failure 
(107)
.  With a usual diameter of 2.5 to 5mm the brachial artery is 
the preferred site of measurement as arteries with smaller diameter are difficult to 
image accurately and reproducibly and very small changes in absolute diameter are 
consequently reported as large percentage changes.  
 
Participants were asked to fast, and avoid caffeine and tobacco for 6 hours prior to 
the test. They were studied in a quiet, temperature-controlled room (23
o
C) and asked 
to lie flat on the bed with 1 pillow under their head. The right arm was extended onto 
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the clamp table. Three ECG leads were placed on the chest and a 
sphygmomanometer cuff placed around right forearm just below the antecubital 
fossa (see Figure 8), as placement of the cuff more distally around the wrist has 
previously been shown to result in a smaller reactive hyperaemia response and lower 
FMD. A 2D image of the brachial artery was recorded in end-diastole, identified by 
the onset of the R-wave for 2 minutes just above the antecubital fossa in the 
longitudinal plane using an Acuson sequoia 512 ultrasound machine with an 8L5 
Transducer. 
 
Figure 8: Positioning for measurement of brachial artery flow mediated dilation 
 
 
 
The cuff was then inflated using a Hokanson rapid cuff inflator (Hokanson Inc., 
Bellview, WA. USA) to 200mmHg or 50 mmHg more than the recorded systolic 
blood pressure (whichever level was higher for 5 minutes and then deflated.  
Previous studies have examined duration times for cuff occlusion 
(108)
 concluding 
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that more than 5 min occlusion duration has been shown to prolong the duration of 
hyperaemia and evoke a non-NO-mediated response. A further 2 minute recording of 
the artery was taken and FMD calculated as the percentage change in the brachial 
artery diameter during hyperaemia compared to the baseline measurement using 
semi–automated analysis software (Brachial Tools edge detection software, Medical 
Imaging Applications, Iowa City, USA). 
 
Secondary Outcome Measures 
Measures of Vascular Function 
Carotid intima-media thickness (IMT) of the common carotid artery has been 
identified as an indicator for cardiovascular disease. An increase in IMT is the 
earliest measurable morphological alteration of the arterial wall 
(109)
. It has been 
recognised as being a highly accurate, easily reproducible test, correlating well with 
pathophysiologic measurements 
(110)
. Hashimoto et al demonstrated direct correlation 
between FMD of the brachial artery and carotid IMT in men 
(111)
, while in a study of 
963 participants carotid IMT was associated with atherosclerotic risk factors, 
increasing with the number of concurrent risk factors even after stratification for age 
(112)
. 
 
Carotid B-mode ultrasonography enables measurement of the thickness of tunica 
intima and tunica media, the innermost two layers of the arterial wall. An increased 
cross-sectional intima-media thickness has been associated with increased risk of 
stroke and myocardial infarction 
(113;114)
 as well as lower extremity atherosclerosis 
(115)
. B-mode scanning of one of the carotid arteries was performed using Siemens 
 66 
Acuson Sequoia 512 using an 8 MHz transducer.   The participant was asked to lie in 
a supine position with the neck extended and the chin turned away from the side 
which was being examined.  The participant’s carotid artery was identified initially 
with the transducer in a transverse plane and then studied longitudinally. The 
common carotid artery was examined with three measurements of the IMT being 
taken at a point on the far wall of the artery just below the carotid bulb (see figure 9). 
Although vessels at different locations throughout the circulatory system may be 
used to assess IMT the carotid arteries are deemed most suitable due to their position, 
size and limited movement with the common carotid artery positioned parallel to the 
skin surface 
(116)
.  
 
Different techniques in the measurement of IMT currently exist with researchers in 
previous studies taking different approaches and carrying out measurements at 
different points of the carotid artery. One approach is to take multiple measurements 
within the three main segments of the artery – the common carotid, bifurcation and 
the internal carotid artery - measuring both the near and far away walls. The maximal 
measurements for each section are recorded and an average is taken.  This approach, 
although widely used, is problematic when areas of the internal carotid artery have 
been difficult to visualise and studies using this method tend to have larger amounts 
of missing data 
(116)
. Alternatively other researchers have recorded the common 
carotid artery near and far wall. 
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Figure 9: Ultrasound View of Carotid Artery and IMT taken from 
(117)
 
 
 
Common carotid IMT was measured approximately 10mm proximal to the carotid 
bulb on each of the three study visits.  Three measurements over a 1cm section were 
taken and the average calculated and recorded in the CRF.   
 
Arterial stiffness can be increased by three key mechanisms: firstly there is a 
breakdown of elastin within the arterial walls, secondly damage occurs to the 
endothelium and thirdly there is an increase in mean arterial pressure. Several 
methods of measuring arterial stiffness currently exist – 
 
Pulse pressure - Pulse pressure is the difference between the peak systolic blood 
pressure (SBP) and peak diastolic blood pressure (DBP). It is dependent on cardiac 
output pressure and can be easily measured using a standard sphygmomanometer. 
Although elevated pulse pressure has been associated with cardiovascular disease 
(118)
  both SBP and DBP  usually increase with age until around the age of 60 years 
when there is usually no further increase in DBP and in many cases it actually 
declines widening the pulse pressure. Pulse pressure alone therefore is inadequate to 
assess arterial stiffness accurately. The ‘normal’ amplification of the pressure wave 
as it travels from the aorta to the periphery becomes less pronounced with increasing 
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age thus measurements of pulse pressure made in the periphery do not always 
accurately reflect the actual central pulse pressure. In fact differences of up to 
20mmHg between central pressures of patients with identical brachial blood pressure 
readings have been recorded. Central pressure may, therefore, be a more accurate 
predictor of risk than peripheral blood pressure. A number of studies have shown that 
pulse pressure is an important predictor of risk. The Framingham study in the US 
demonstrated that in hypertensive patients over the age of 50 years, the pulse 
pressure was a better predictor of coronary heart disease risk than either systolic or 
diastolic pressure alone 
(119)
. 
Pulse Wave Analysis (PWA) is a method of measuring aortic pressure wave. It was 
first established back in the late 1800s by Frederick Akbar Mohamed who identified 
the difference between the carotid and radial waveform using the sphygmograph 
(120)
.  
Following the invention of the sphygmomanometer however the recording of 
diastolic blood pressure became more widely used as the primary indicator of 
cardiovascular risk 
(121)
 with studies such as the Framingham study clearly 
demonstrating the link between blood pressure and cardiovascular disease. 
(74)
.   It 
can be argued however that while BP has been shown to be a significant factor 
associated with the risk of cardiovascular disease the brachial artery routinely used to 
measure BP may not be as affected by atherosclerosis and thus the measurement of 
the ascending aortic pressure may be a better predictor 
(122)
.   
 
PWA and Pulse Wave Velocity (PWV), two techniques of recording changes in the 
central aorta which have arisen from the loss of arterial elasticity can be assessed 
easily using the Sphygmograph.  
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The systolic pulse wave in the central aorta is amplified by the reflection of blood 
from arterial bifurcation points, primarily that of the distal aorta itself. A perfectly 
elastic aorta will absorb the entire pulse wave produced by ventricular contraction 
however a completely stiff and rigid tube will reflect a large proportion of the wave. 
The pulse pressure waveform differs in different blood vessels in the same 
individual, and is reliant on several things; the viscoelastic properties of the artery; 
the viscosity of the blood; the wave reflection and the wave dispersion. 
 
Wave reflection leads to amplification of the aortic pressure wave. This wave travels 
from the left ventricle to the periphery where it reaches vessels of greater impedance 
that act as a mirror, reflecting it back to the aorta. Thus the resulting pressure in the 
ascending aorta is the sum of the incident and reflected wave and is dependent on the 
heart rate, the speed of the pulse wave and the amplitude of the reflected pulse wave 
(see figure 10). 
Figure 10: Diagram of a pulse wave taken from 
(123) 
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For a given heart rate, the time of arrival of the reflected wave depends on the PWV, 
which is in turn determined by how stiff the vasculature is. If the reflected wave 
arrives early in the cardiac cycle it combines with the incident wave giving a greater 
ascending aortic pressure against which the left ventricle has to pump; however, if it 
arrives later in the cardiac cycle it increases the ascending aortic pressure in diastole, 
leading to improved coronary circulation. The Augmentation Index (Alx), because of 
its correlation with PWV - which has been shown to be dependent on arterial 
stiffness - has been proposed as a marker for arterial stiffness.  
  
PWV is calculated by measuring the time it takes for the arterial waveform to pass 
between sites (usually the carotid and radial, or carotid and femoral) two points 
which are a measured distance apart, and involves taking the readings 
simultaneously, or by gating separate recordings to a fixed point in the cardiac cycle, 
usually the R wave of the ECG.  
 
The relationship between how stiff arteries are and the speed of the pulse wave was 
first predicted by Thomas Young in 1808 and is described as a mathematical 
equation - The Moens-Korteweg equation or PWV=√Eh/2ρR. PWV is calculated 
from measurements of pulse transit time and the distance travelled by the pulse 
between two recording sites: PWV=Distance (metres)/Transit Time (seconds). 
Various different methods are available, both invasive and non‐invasive, but the 
development of modern tonometer systems has enabled the measurement of accurate 
pressure waveforms without the need for invasive catheter-based measurements. 
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The SphygmoCor system used in this study has a transfer function which can be used 
to calculate central pressure from the radial pulse waveform, using a hand-held 
tonometer. The SphygmoCor can also be used at other superficial arterial sites 
including the carotid and femoral arteries, and by ECG-gating, the time for 
transmission of the arterial pulse wave between sites (PWV) is calculated. 
 
The SphygmoCor (version 7.1) is a recently-developed computerized, portable and 
simple-to-use device validated to assess pulse waveforms and assess arterial stiffness 
(124)
. Aortic pulse waveform, Alx, and central aortic pressure were derived at the 
radial artery by applanation tonometry. For this study the radial and carotid artery 
sites were used mainly due to ease of access.  
 
The participant was asked to lie in a relaxed, comfortable position with their arm 
extended across a flat hard surface, palm of the hand facing upward. The radial and 
carotid artery pressure waves and amplitude were recorded non-invasively with a 
pencil-type probe (at the base of neck for the common carotid artery and over the 
right radial artery).  
 
The probe incorporates a transducer at the tip, which has a small pressure-sensitive 
ceramic sensor area with a frequency response of >2 kHz that is coplanar with a 
longer area (7mm diameter) of flat surface in contact with the skin overlying the 
arterial pulse. The probe's technology is based on the principle of applanation 
tonometry, as used in ocular tonometry for the assessment of intraocular pressure. 
The probe was held on the skin over the maximal arterial pulsation by hand and 
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pressed down on the artery against the underlying bone (Figure 11). Recordings were 
taken when a reproducible signal was obtained with high amplitude excursion 
(usually 10 consecutive beats to cover a complete respiratory cycle are needed for 
subsequent analysis).   
 
A quality control mechanism for both PVW and Alx is built into the SphygmoCor 
system and this was used to ensure that all data recorded was of an adequate quality 
for analysis. All PVW data had a SD of less than 10% of the velocity with the system 
highlighting clearly if the reading had not been of sufficient quality.  The Alx was 
calculated by a computer algorithm derived from invasive pressure and flow data, 
and recorded as a percentage. Three successful readings where recorded for the Alx 
with the median value recorded in the CRF 
 
Both Alx and PWV were recorded. It has been found in previous studies that these 
two measures of arterial stiffness correlate significantly with each other.  
Figure 11:  Diagram of applanation tonometry process being taken. 
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Research has shown that PWV is a more reliable measure of arterial stiffness in the 
older population than Alx. The recording of PWV is a valid and reproducible and 
relatively simple procedure which can be learned fairly easily. Outcome data has 
shown PWV to be an independent predictor of cardiovascular risk in both 
hypertensive patients and patients with end‐stage renal disease (125;126). 
 
Measures of Vascular Prognosis 
B-type Natriuretic Peptide (BNP)  
A 10ml sample of venous blood was taken in a purple vacutainer containing 
potassium EDTA during both the baseline visit and the 6 month follow–up visit. On 
each occasion the sample was placed on ice and then centrifuged at 3000rpm at 4°C 
for 10 minutes. The plasma was removed from the sample and then placed in a 5ml 
sample bottle which was stored in a -70°C freezer until all 80 participants had 
completed the study at which point all samples were assayed. All 80 baselines and 
follow-up visit samples were assayed using the Bachem radio immune assay kit 
(Bachem, Peninsula Laboratories, Inc, US). 
 
Atrial Natriuretic peptide (ANP) and Brain-type Natriuretic Peptide (BNP) belong to 
a family of peptide hormones and are both secreted in the cardiac ventricles in 
response to volume expansion and pressure overload. 
 
The main actions of ANP and BNP include natriuresis, diuresis, and inhibition of the 
renin-angiotensin-aldosterone system and thereby play an important role in 
regulating blood pressure and blood volume 
(127)
.  
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ANP is secreted as a direct response to atrial stretch while BNP is produced in the 
left ventricle as a direct response to elevated left ventricular pressure 
(128)
.  Elevated 
BNP levels have been used to identify the presence of heart failure as well as a range 
of cardiovascular diseases such as atrial fibrillation and valvular disease in an elderly 
population 
(129)
, and are found to be elevated with the presence of essential 
hypertension 
(130)
.  
 
A study of elderly functionally impaired adults with multiple comorbidity found 
elevated BNP to be an independent predictor of all cause and cardiovascular 
mortality, more significant than blood pressure, diabetes or age, and predictive of 
death in those in older functionally impaired patients with multiple comorbid disease 
with or without previous cardiovascular history 
(131)
.  
 
C-reactive protein (CRP)  
A 3ml sample of venous blood from each participant was collected in a gold 
vacutainer at baseline and six month follow up. The sample was then kept for a 
minimum of ten minutes before being centrifuged at 3000rpm for ten minutes at 4°C. 
Serum was extracted from the centrifuged sample, placed in a 1ml sample tube and 
transferred to a -80°C freezer and stored until the last participant had completed the 
study. 
 
C-reactive protein (CRP) is a 224-residue protein which is found circulating in the 
blood where its levels are found to increase in response to inflammation, trauma and 
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infection only to decrease just as quickly with the resolution of the condition 
(128)
. 
The measurement of CRP is widely used to monitor various inflammatory states such 
as Rheumatoid Arthritis 
(129)
 and used as part of a wider assessment along with 
clinical and laboratory information to manage acute bacterial infections 
(132)
. More 
recently research has shown that inflammatory processes have an active role to play 
in atherogenesis 
(133)
.  
 
CRP has been found to be a baseline predictor of future cardiovascular events in 
apparently healthy men 
(134)
 while individuals with elevated levels of CRP have a risk 
2 to 3 times higher than the risk of those with low levels.  The American Heart 
Association 
(135)
 classified  levels obtained using “high sensitivity” CRP assays as 
follows:  less than 1 mg/L is desirable and reflects a low overall cardiovascular risk.; 
levels between 1 and 3 mg/L are indicative of moderate risk, while levels of CRP in 
excess of 3 mg/L suggest elevated vascular risk. 
 
CRP, which can be measured inexpensively with high sensitivity assays, has been 
shown to identify increased risk of future cardiovascular events in stroke 
(136) 
and 
PVD 
(137)
 as well as being associated with incident events in the elderly, especially in 
those with subclinical disease at baseline 
(138)
.  
 
In a study looking at the use of statins in the prevention of coronary events, CRP was 
an independent predictor of cardiovascular disease with statins being effective in 
reducing levels of CRP even in participants with relatively low lipid levels. 
(139)
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Ridker et al showed that CRP was in fact a better predictor of cardiovascular risk that 
low-density lipoprotein (LDL) cholesterol 
(140)
.  
 
All samples were analysed in Professor Allan Struthers’ laboratory in Ninewells 
Hospital by Ms. Lesley McFarlane using a microplate-based EIA (ELISA) double 
antibody sandwich assay for C-reactive protein from Kalon Biological Ltd. 
 
Serum Cholesterol 
Total cholesterol, HDL cholesterol and LDL cholesterol were collected at baseline 
and 6 months. Patients were fasted for a minimum of 5 hours prior to collection of a 
3ml sample collected in gold vacutainer. Following collection blood samples were 
delivered to the Biochemistry Department at Ninewells Hospital, Dundee for analysis 
reports returning within 48 hours to RF.  
  
 
Serum MK7 Level 
Fasting vitamin K1 reference values in healthy adults range from 0.15 to 1.0 μg/L 
(median 0.5 μg/L) (141).  A 3ml sample of venous blood from each participant was 
obtained as for CRP collection and stored in the -80°C freezer until the last 
participant had completed the study.  
All samples were analysed within the department laboratory by Dr Sandy Hill using 
high-performance liquid chromatography, using cetyl naphthoate 
(140)
, synthesised in 
house, as internal standard and based on a previously validated method for assay in 
human serum 
(141). 
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Measures of Physical Function 
Physical function along with exercise capacity decline with age and are a major 
source of disability in older people 
(142)
. Testing physical function has been shown to 
be an accurate indicator of current health status, be predictive of future health and 
disability, and may be used to predict the likelihood of health and social care use in 
the future 
((143)
. Function may be assessed by either self-reported questionnaires or by 
tests of physical performance. 
 
Short Physical Performance Battery (SPPB) 
Participants were asked to participate in a short physical function test, which was 
repeated at 6 months. The three-part test was explained fully and commenced only 
after the participant had had the opportunity to rest for 5 minutes.  Each part of the 
test was demonstrated by the researcher and scores were obtained by the participant 
for each of the three parts: balance testing; gait speed testing and chair speed testing 
and entered into the CRF under the relevant section (see appendix 8 for SPPB 
scoring sheet and protocol.) The test focuses on lower limb function using tasks that 
mimic daily activities and includes a timed 4 metre walk to measure gait speed; one 
chair stand followed by 5 timed chair stands, if the first is successfully completed; 
and finally balance stands with the feet held in 3 different positions for 10 seconds 
each. These areas represent essential tasks important for independent living and are 
thus an important outcome measure for patients with cardiovascular disease.  Any 
part of the test either not attempted or not completed by the participant automatically 
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scored a zero and was entered into the CRF while standardised encouragement was 
offered at various points during the test. 
 
Standardised physical performance tests have been increasingly used in ageing 
research and have been found to be positively associated with health status as well as 
being predictive of outcomes such as hip fracture, nursing home admission and death 
(144)
.  Evidence also exists that these tests are suitable for use in non-disabled adults 
(145)
 as well as being able to identify those who are at increased risk for the onset of 
functional dependence 
(146;147)
. 
The SPPB is an objective assessment tool for evaluating lower extremity functioning 
in older persons and has been designed to measure physical performance and decline 
over time. It was developed by the National Institute on Aging and is freely available 
for use without permission or the payment of royalty fees. Performance tests have 
increasingly been associated with measures of health status and the SPPB has indeed 
been found to be predictive of long term disability and of future institutionalisation 
(148)
. A 4 year prospective cohort study of older, non-disabled older adults found that 
those with the poorest lower extremity performance at baseline spent significantly 
more days in hospital (17.7 v 9.7 days) when compared to those who had recorded a 
high performance even after adjustment for baseline chronic conditions 
(149)
. In a 
recent study comparing the predictive value for mortality of several different 
performance measures, the SPPB score emerged as the strongest predictor of 
mortality in elderly community dwelling participants with the chair stand  subtask 
showing highest predictive value 
(150)
. The test is easily administered, takes around 
10 minutes to complete and can be easily reproduced.  
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Hand Grip Dynamometry 
Handgrip dynamometry is a simple test used to directly measure muscle strength. All 
participants’ handgrip strength was assessed at both baseline and the 6 month follow-
up visit using the T.K.K 5001 Grip – A hand held dynamometer (Takei Scientific 
Instruments Company Ltd, Japan). Each participant was asked to identify their 
dominant hand before taking the dynamometer with the non-dominant one. The grip 
width was adjusted so that the second joint of the pointing finger made a right angle 
when using the instrument.  In a standing immobilised position, in order to minimise 
the contribution to the measured force from muscle groups in other areas of the body, 
with the arm hanging by their side, the participant was asked to squeeze as tightly as 
possible and then return the dynamometer back to the researcher who recorded the 
reading given in kilograms. This procedure was repeated a total of three times with 
the highest of the three readings recorded in the CRF for use in analysis. 
 
Hand grip strength has been found to correlate with strength of other muscle groups 
and is thus a good indicator of overall strength 
(151)
. A study among healthy 45 to 68 
year old men, found it to be highly predictive of functional limitations and disability 
25 years later and concluded that good muscle strength in midlife may protect people 
from old age disability 
(152)
 
 
Rantanen et al examined the association between muscle strength and total and 
cause-specific mortality in older disabled women concluding that hand grip strength 
was indeed a powerful predictor of cause-specific and total mortality 
(153)
 while 
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Cheung et al demonstrated that handgrip strength was associated with multi 
morbidity, and that handgrip strength may be a more useful marker of this than 
chronological age in men. Furthermore, they also demonstrated that handgrip 
strength was associated with different chronic diseases (154), while in a  recent 
population-based cohort study based in Sweden of one million men, reduced 
handgrip strength was associated with increased risk of incident coronary heart 
disease and all strokes 
(155),   
 
Follow-up visits 
Participants returned at 3 months for assessment of outcomes (FMD; PWV and 
Carotid IMT); lying and standing BP were also recorded. (Fig 12). Medication 
adherence was assessed and recorded as was any change to life circumstance or 
medical history. The 6 month follow-up visit repeated the assessments of handgrip 
strength; SPPB; serum cholesterol; BNP and CRP in addition to those carried out 
during the 3 month visit. 
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Figure 12: Schedule of study visits 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Screening – baseline visit (0 month) 
ECG, consent, demographics, past medical history, concomitant medication, 
lying & standing BPs & falls history, 
Baseline outcomes measured: FMD, PWV, Carotid IMT, hand grip strength, 
SPPB, blood samples for CRP & BNP 
Blood samples for safety bloods, U&E’s & INR 
Study medication issued 
 
 
 
 
 
 
Follow-up visit - (3 month) 
Outcome measures – FMD, PVW, 
Carotid IMT 
Lying & standing BP & Falls history 
Medication adherence  
 
Follow-up visit - (6 month) 
Baseline outcomes measured: FMD, PWV, Carotid IMT, 
hand grip strength, SPPB, 
blood samples for CRP & BNP 
Lying & standing BP & Falls history 
Medication adherence 
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2.9   Data Handling 
Data Entry and Management  
The researcher recorded data for each participant on the CRF during each study visit. 
Other data such as log sheets for study medication, adverse events, serious adverse 
events and specimen storage were also recorded and kept securely within the 
department of Ageing and Health, University of Dundee.  
All data were entered into an Excel spread sheet by the researcher at regular intervals 
during the study in preparation for data analysis. Missing data for each time point 
was excluded from the initial analysis of outcome measures. 
 
Data Analysis 
All data were analysed using SPSS statistical package (Version 21.0). Analyses of 
the primary and secondary outcomes were performed prior to breaking the treatment 
codes. A 2-sided p value of < 0.05 was taken to be significant for all analyses.  
Differences between treatment groups for outcome measures were assessed. Baseline 
data were compared between groups using an independent samples t-test for all 
normally distributed data, and Mann Whitney test for non-normally distributed data. 
Categorical variables were compared at baseline using Pearson’s Chi-squared test. 
 
All analyses of treatment effect were conducted according to the principles of 
intention to treat analysis. For each outcome, change scores (follow-up minus 
baseline) were calculated for each follow-up time point, Change scores were tested 
for normal distribution, and compared between groups for each follow-up time point 
using analysis of covariance (ANCOVA) models. Unadjusted analyses were 
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calculated, and adjusted analyses were performed, adjusting for a) age, b) baseline 
value of the outcome variable under test, and c) (for vascular outcomes only) systolic 
blood pressure.  
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3. RESULTS 
3.1  Recruitment 
Participants were recruited from 2 GP practices using the East of Scotland node of 
the SPCRN.  Recruitment took place between January 1
st
 2012 and September 30
th
 
2012. 
 
Two GP practices approached by the SPCRN agreed to participate with a search of 
their databases identifying 991 potential participants. All those identified as 
potentially suitable were contacted by letter and of the 991 letters sent 143 (14%) 
responded indicating their interest in the study. Practice A obtained 74/541 (14%) 
positive replies while invitations sent to patients from Practice B resulted in 69/450 
(15%) positive replies. Recruitment was divided equally between the two practices.  
 
A total of 97 people were contacted by telephone and screened further to assess 
eligibility; the remaining respondents were not contacted as the recruitment target 
had been reached, and these respondents were thanked for their interest. Of the 97 
people, 8 felt unable to participate due to ill health or family commitments while 4 
people were deemed ineligible following the telephone discussion and a more 
detailed check of their medical notes. One individual was found to already be 
enrolled in an on-going hypertension study.  
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In total 84 potential participants were invited to attend the detailed screening / 
baseline visit at Ninewells Hospital. One person was unsuitable to participate due to 
the presence of atrial fibrillation on their ECG recording, while 3 people agreed to 
take part but failed to attend the screening visit (see Figure 13 for CONSORT 
diagram and participant flow through the study). Thus 80 people were recruited and 
randomised. 
 
Figure 13: CONSORT diagram showing participant flow through trial 
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3.2 Baseline Characteristics 
Of the 80 participants who were randomised to the trial, 55% (44/80) of these were 
male with the participants’ mean age being 77 (SD 5) years (Table 4). More than a 
quarter were aged 80 years or over. Over a third lived alone and only 10% (8/80) 
required any formal help at home.  Eighteen percent (14/80) required the use of a 
walking aid to mobilise, while 13% (10/80) of participants smoked despite their 
medical history. 
 
Ninety percent (72/80) of all participants had been given a diagnosis of hypertension 
with 93% (74/80) currently on active antihypertensive treatment. Despite this, blood 
pressure control was suboptimal, with the mean supine blood pressure 153/82 mmHg 
at the baseline visit. Table 6 shows baseline characteristics of all 80 randomised 
participants. 
 
Participants were generally well matched between the two groups with a few notable 
exceptions. Of the participants in the vitamin K supplemented group, 18/40 (45%) 
lived alone, significantly more than in the placebo group 10/40 (25%).  The vitamin 
K group were on significantly more medication than the placebo group, and PWV 
was significantly higher in the placebo group than the vitamin K group.  
 
Dropout during the six month follow-up period was very low; 77/80 (96%) of 
participants completed the final follow-up visit. 
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Table 6: Baseline characteristics of randomised participants  
 
 Vitamin K 
(n=40) 
Placebo 
(n=40) 
p 
Mean Age (years) (SD) 76.0 (4.4) 77.1 (4.8) 0.31 
Male sex (%) 21 (53) 23 (58) 0.37 
Mean Systolic Blood Pressure (mmHg) 
Mean Diastolic Blood Pressure (mmHg) 
144 (17) 
81 (11) 
148 (20) 
83 (10) 
0.33 
0.39 
Past Medical history 
Hypertension (%) 
Previous stroke / TIA (%) 
Previous Myocardial Infarction (%) 
Angina (%) 
CABG/PTCA (%) 
Diabetes Mellitus (%) 
Peripheral Vascular Disease (%) 
Osteoarthritis (%) 
 
 
36 (90) 
8 (20) 
7 (18) 
11 (28) 
7 (18) 
9 (23) 
5 (13) 
16 (40) 
 
36 (90) 
9 (23) 
8 (20) 
7 (18) 
5 (13) 
9 (23) 
3 (8) 
9 (23) 
 
1.00 
0.79 
0.78 
0.30 
0.76 
1.00 
0.46 
0.15 
Social history 
Walking aid (%) 
Lived alone (%) 
Home help (%) 
Current smoker (%) 
 
 
10 (25) 
18 (45) 
4 (10) 
3 (8) 
 
4 (10) 
10 (25) 
4 (10) 
7 (18) 
 
0.24 
0.006                 
1.0 
0.26 
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Medications 
On Antiplatelet medications (%) 
On ACEi / ARB (%) 
On Beta blocker (%) 
On Calcium Channel Blockers (%) 
On other antianginals (%) 
On statins (%) 
Median total no. of medications (IQR)* 
 
 
25 (63) 
30 (75) 
8 (20) 
20 (50) 
7 (18) 
26 (65) 
8 (5) 
 
18 (45) 
25 (63) 
10 (25) 
14 (35) 
3 (8) 
27 (68) 
5 (4) 
 
0.12 
0.23 
0.59 
0.18 
0.81 
0.31 
<0.001 
Baseline Outcome measures  
Mean Flow Mediated Dilatation (%)(SD) 
Mean Pulse Wave Velocity (m/s) (SD) 
Mean Carotid IMT (cm) (SD) 
Median Grip Strength kgs (IQR)* 
Median SPPB score (IQR)* 
 
 
6.3 (2.7) 
9.7 (2.1) 
0.077(0.015) 
25.8 (13.0) 
8.8 (2.4) 
 
7.3 (2.4) 
10.7 (2.3) 
0.080(0.021) 
27.3 (13.3) 
9.3 (2.4) 
 
0.24 
0.05 
0.50 
0.20 
0.25 
Blood Results 
Mean serum Sodium (mmol/L) (SD) 
Mean serum Creatinine(umol/L) (SD) 
Median Urea (mmol/L) (IQR) * 
Median BNP level (pg/ml) (IQR)* 
Median CRP level (mg/L) (IQR)* 
Mean Total Cholesterol (mmol/L) (SD) 
Median Vitamin K2 levels (pg/ml) (IQR) 
 
140 (3) 
79 (22) 
6.4 (3.1) 
33 (29) 
1.8 (2.1) 
4.7 (1.1) 
476 (301) 
 
140 (2) 
83 (18) 
6.9 (2.7) 
33 (22) 
1.8 (2.1) 
4.7 (1.1) 
502 (242) 
 
0.97 
0.16 
0.59 
0.42 
0.34 
0.99 
0.43 
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CABG- coronary artery bypass graft;  
PTCA - percutaneous transluminal coronary angioplasty;  
ACEi – angiotensin-converting-enzyme inhibitor;  
ARB - angiotensin receptor blocker;  
IMT – intima-media thickness;  
SPPB - short physical performance battery;  
BNP - B-type natriuretic peptide;  
CRP – C-reactive protein 
* Data analysed using Mann-Whitney tests for non-parametric tests 
 
3.3   Outcome Measures 
Primary outcome 
The primary outcome measure of change in mean FMD is given in Table 7. No 
significant treatment effect was seen for between-group change at either 3 months or 
6 months; adjustment for baseline FMD, systolic blood pressure and age did not 
affect the outcome. 
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 Table 7. Effect of Intervention on Flow Mediated Dilatation of the Brachial 
Artery 
Time Vitamin K Placebo P 
Baseline visit (%) (SD) 6.3 (2.7) 7.3 (2.4) 0.24 
3 month visit  (%) (SD) 7.1 (2.5) 7.0 (3.0) 0.90 
6 month visit  (%) (SD) 7.6 (2.7) 8.6 (2.4) 0.79 
Treatment Effect (0 v 3 months) (%) (95% CI) 0.9 (-0.7 to 2.5) 0.26 
Adjusted Treatment Effect *  
(0 v 3 months) (%) (95% CI) 
0.4 (-0.9 to 1.8) 0.51 
Treatment Effect (0 v 6 months) (%) 0.1 (-1.0 to 1.2) 0.87 
Adjusted Treatment Effect * 
(0 v 6 months) (%) (95% CI) 
-0.3 (-1.3 to 0.8) 0.62 
 
*adjusted for baseline flow-mediated dilatation, age and systolic blood pressure 
Participants at each visit: baseline n= 78; 3 month visit n= 73; 6 month visit n= 74 
 
Secondary outcomes 
Vascular Markers 
No significant treatment effect was noted for carotid IMT (Table 8) and this also did 
not change after adjustment for baseline values. Pulse wave velocity (Table 9) and 
augmentation index (Table 10) also did not show any significant change with 
treatment, pulse wave velocity, although by six months, pulse wave velocity had 
fallen by 0.8 m/s in the vitamin K group relative to placebo after adjustment for 
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baseline values. This was despite a significant baseline difference between the 
groups, with the vitamin K group starting with a lower baseline value (9.7 vs. 10.7 
m/s) 
 
Table 8. Effect of intervention on Carotid Intima-Media Thickness 
Time Vitamin K Placebo P 
Baseline visit (cm) (SD) 0.07 (0.015) 0.08 (0.021) 0.50 
3 month visit (cm) (SD) 0.078 (0.013) 0.078 (0.010) 0.80 
6 month visit (cm) (SD) 0.076 (0.020) 0.080 (0.010) 0.36 
Treatment Effect (0 v 3 months) (cm) (95% CI) 0.004 (-0.003 to 0.011) 0.23 
Adjusted Treatment Effect* (0 v 3 months) (cm) 
(95% CI) 
0.003 (-0.002 to 0.007) 0.21 
Treatment Effect (0 v 6 months) (cm) (95% CI) 0.001 (-0.008 to 0.009) 0.89 
Adjusted Treatment Effect* (0 v 6 months) (cm) 
(95% CI) 
0.003 (-0.002 to 0.007) 0.78 
*adjusted for baseline carotid intima-media thickness and baseline age 
Participants at each visit: baseline n= 79; 3 month visit n= 77; 6 month visit n= 76 
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Table 9. Effect of Intervention on Pulse Wave Velocity 
Time Vitamin K Placebo P 
Baseline visit (m/s) (SD) 9.7 (2.1) 10.7 (2.3) 0.05 
Visit 2 (m/s) (SD) 10.0 (3.1) 10.2 (1.7) 0.71 
Visit 3 (m/s) (SD) 9.9 (1.4) 10.9 (3.0) 0.08 
Treatment Effect (0 v 3 months) (m/s) (95% CI) 0.6 (-0.9 to 2.0) 0.44 
Adjusted Treatment Effect* (0 v 3 months) (m/s) 
(95% CI) 
-0.1 (-1.4 to 1.3) 0.91 
Treatment Effect (0 v 6 months) (m/s) (95% CI) -0.3 (-1.5 to 0.8) 0.58 
Adjusted Treatment Effect* (0 to 6 months) (m/s) 
(95% CI) 
-0.8 (-1.8 to 0.3) 0.15 
*adjusted for baseline pulse wave velocity, systolic blood pressure and age 
Participants at each visit: baseline n= 76; 3 month visit n= 73; 6 month visit n=76 
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Table 10. Effect of Intervention on Augmentation Index 
Time Vitamin K Placebo P 
 
Baseline visit (%) (SD) 28 (10) 28 (7) 0.92 
3 month (%) (SD) 26 (9) 28 (6) 0.47 
6 month (%) (SD) 25 (8) 27 (6) 0.54 
Treatment Effect (0 v 3 months) (%) (95% CI) -1 (-5 to 3) 0.55 
Adjusted Treatment Effect* (0 v 3 months) (%) 
(95% CI) 
-1 (-5 to 2) 0.46 
Treatment Effect (0 v 6 months) (%) (95% CI) -1 (-5 to 3) 0.54 
Adjusted Treatment Effect* (0 v 6 months) (%) 
(95% CI) 
-2 (-5 to 2) 0.32 
 
*adjusted for baseline augmentation index, age and systolic blood pressure 
Participants at each visit: baseline n= 80; 3 month visit n= 76; 6 month visit n=75 
 
 
There was no significant change in either systolic or diastolic blood pressure in either 
group (Table 11). Mean systolic blood pressure (SBP) fell over the six month follow 
up period in both groups, but fell by a greater amount in the placebo group. 
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Table 11. Effect of Intervention on Blood Pressure 
 Vitamin K Placebo P 
 
Systolic blood pressure 
Baseline visit (mmHg) (SD) 144 (17) 148 (20) 0.33 
3 month visit (mmHg) (SD) 141 (16) 144 (17) 0.36 
6 month visit (mmHg) (SD) 140 (17) 140 (18) 0.86 
Treatment Effect (0 v 3 months) (mmHg) (95% CI) 0 (-8 to 9) 0.91 
Adjusted Treatment Effect* (0 v 3 months) (mmHg) 
(95% CI) 
-1 (-8 to 6) 0.72 
Treatment Effect (0 v 6 months) (mmHg) (95% CI) 3 (-5 to 11) 0.53 
Adjusted Treatment Effect* (0 v 6 months) (mmHg) 
(95% CI) 
1 (-6 to 8) 0.75 
Diastolic blood pressure 
Baseline visit (mmHg) (SD) 81 (11) 83 (10) 0.39 
3 month visit (mmHg) (SD) 82 (9) 82 (9) 0.98 
6 month visit (mmHg) (SD) 80 (9) 80 (9) 0.98 
Treatment Effect (0 v 3 months) (mmHg) (95% CI) 2 (-2 to 6) 0.38 
Adjusted Treatment Effect* (0 v 3 months) (mmHg) 
(95% CI) 
1 (-3 to 4) 0.65 
Treatment Effect (0 v 6 months) (mmHg) (95% CI) 2 (-2 to 6) 0.39 
Adjusted Treatment Effect* (0 v 6 months) (mmHg) 
(95% CI) 
1 (-3 to 5) 0.65 
*adjusted for baseline blood pressure and age 
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Measures of Physical Function 
No change was noted in handgrip strength between baseline and follow-up with a 
measure of treatment effect giving a non-significant result (Table 12). The maximum 
possible score on the SPPB is 12. Although these data were skewed at each 
timepoint, change scores between timepoints were normally distributed, and thus 
mean values for change are presented in Table 13.  
 
Table 12. Effect of intervention on Grip Strength 
Time Vitamin K Placebo P 
Baseline visit (Kg) (SD) 26.2 (9.3) 29.1 (9.0) 0.16 
6 month (Kg) (SD) 26.7 (9.8) 29.0 (8.8) 0.29 
Treatment Effect (0 v 6 months) (Kg) (95% CI) 0.1 (-1.0 to 1.2) 0.83 
Adjusted Treatment Effect* (0 v 6 months) (Kg)  
(95% CI) 
-0.1 (-1.0 to 1.2) 0.87 
*adjusted for baseline grip strength and age 
Participants at each visit: baseline n= 80; 6 month visit n= 77 
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Table 13. Effect of Intervention on Short Physical Performance Battery Scores 
Time Vitamin K Placebo P 
Median score baseline visit (IQR) 9 (4) 10 (3) 0.25 
Median score 6 month visit (IQR) 9 (3) 10 (4) 0.21 
Mean treatment Effect (0 v 6 months) (95% CI) -0.3 (-1.0 to 0.3) 0.29 
Adjusted mean treatment Effect* (0 v 6 months)  
(95% CI) 
-0.5 (-1.1 to 0.2) 0.14 
Participants at each visit: baseline n= 80; 6 month visit n= 77 
 
 
Blood Tests 
B-type Natriuretic Peptide (BNP) and C-reactive protein (CRP) levels 
Similarly, data at baseline and 6 month follow-up were not normally distributed for 
BNP and CRP thus between group comparisons were performed using Mann 
Whitney tests. Change scores were however normally distributed, thus mean values 
are given and ANOVA was used to compare change scores between groups. Results 
are given in Tables 14 and 15; no significant between-group differences were seen 
even after adjustment for baseline values. 
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Table 14. Effect of intervention on B-type Natriuretic Peptide levels 
Time Vitamin K Placebo P 
Median baseline visit (pg/ml) (IQR) 33 (29) 33 (22) 0.83 
Median 6 month visit (pg/ml) (IQR) 40 (24) 37 (29) 0.30 
Mean treatment effect (0 v 6 months) (pg/ml)  
(95%) CI 
8 (-8 to 23) 0.33 
Adjusted mean treatment effect* (0 v 6 months) 
(pg/ml) (95% CI) 
8 (-8 to 24) 0.31 
*adjusted for baseline B-type natriuretic peptide level, age and systolic blood 
pressure 
 
Table 15. Effect of intervention on C-reactive protein levels 
Time Vitamin K Placebo P 
Median Baseline visit (mg/L) (IQR) 1.8 (3.3) 1.4 (2.1) 0.76 
Median 6 month visit  (mg/L) (IQR) 1.8 (3.5 1.8 (2.6) 0.82 
Mean treatment effect (0 v 6 months) (mg/L)  
(95% CI) 
1.8 (-4.7 to 8.3) 0.58 
Adjusted mean treatment Effect* (0 v 6 months) 
(mg/L) (95% CI) 
-0.1 (-3.8 to 3.5) 0.94 
*adjusted for baseline C-reactive protein and age 
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Serum cholesterol  
Baseline total cholesterol level was identical between the two groups at 4.7mmol/L 
(SD 1.1). High cholesterol was a documented past medical history in a high 
percentage of participants with 26/40 (65%) of the vitamin K group and 27/40 (68%) 
of the placebo group prescribed statin therapy at baseline. Table 16 shows no 
significant difference in either total cholesterol, HDL cholesterol or LDL cholesterol 
between either group at either baseline or six months. 
 
Serum vitamin K 
Vitamin K2 levels rose in the intervention arm compared to placebo (+48 pg/ml vs -6 
pg/ml, p=0.03) at six months compared to baseline, confirming that the study 
intervention successfully raised circulating vitamin K2 levels. 
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Table 16: Effect of intervention on Serum Cholesterol 
Time Vitamin K Placebo P 
Total cholesterol 
Baseline visit (mmol/L) (SD) 4.7 (1.1) 4.7 (1.1) 0.99 
6 month visit  (mmol/L) (SD) 4.6 (1.1) 4.5 (1.1) 0.73 
Treatment Effect (0 v 6 months) (mmol/L) (95% CI) 0.0 (-0.3 to 0.3) 0.96 
Adjusted Treatment Effect* (0 v 6 months) 
(mmol/L) (95% CI) 
0.0 (-0.2 to 0.3) 0.79 
HDL cholesterol 
Baseline visit (mmol/L) (SD) 1.5 
(0.5) 
1.5 
(0.6) 
0.72 
6 month visit  (mmol/L) (SD) 1.4 
(0.5) 
1.4 
(0.4) 
0.47 
Treatment Effect (0 v 6 months) (mmol/L) (95% CI) 0.0 (-0.1 to 0.1) 0.90 
Adjusted Treatment Effect* (0 v 6 months) (mmol/L) 
(95% CI) 
0.0 (-0.1 to 0.1) 0.77 
LDL cholesterol 
Baseline visit (mmol/L) (SD) 3.3 
(1.0) 
3.3 
(1.1) 
0.89 
6 month visit  (mmol/L) (SD) 3.3 
(0.9) 
3.4 
(1.0) 
0.81 
Treatment Effect (0 v 6 months) (mmol/L) (95% CI) -0.1 (-0.4 to 0.3) 0.67 
Adjusted Treatment Effect* (0 v 6 months) (mmol/L) 
(95% CI) 
-0.1 (-0.3 to 0.2) 0.73 
HDL: High-density lipoprotein. LDL: Low-density lipoprotein 
*adjusted for baseline cholesterol and age 
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3.4   Major Recorded Adverse Events 
Serious Adverse Events 
A total of 6 serious adverse events (SAE) i.e. those resulting in hospitalisation or 
death were recorded, with 4 in the vitamin K group and 2 in the placebo group (see 
Table 17). One participant died following a myocardial infarction which occurred 
during participation in an exercise event prior to the final study visit while the five 
other hospital admissions were also unrelated to study participation. 
 
Table 17 Record of Serious Adverse Events 
 
System 
 
Vitamin K 
 
Placebo 
Hospital 
admissions 
Death Hospital 
admissions 
Death 
Cardiovascular 1 
(pulmonary 
oedema) 
1 
(following 
myocardial 
infarction) 
0 0 
Musculoskeletal 
 
2 
(falls; one 
fracture) 
0 
 
0 0 
Gastrointestinal 0 0 2 
(1 dehydration, 1 
planned surgical 
admission) 
0 
Hospitalisation 3 2 
Death 1 0 
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Adverse Events 
Table 18 shows the total number of adverse events over the six month study period. 
More adverse events (42 vs. 35) were recorded by the vitamin K group than placebo, 
with gastrointestinal disturbance and falls mainly accounting for the excess of events.  
 
There were 17 falls recorded in the vitamin K group, two of which required 
hospitalisation, and one of which had sustained a fractured wrist. Logistic regression 
analysis was carried with variables in the equation: group; walking aid; living alone; 
baseline grip strength; osteoarthritis; and medication burden at baseline. Risk of 
having sustaining a fall depending on group was 0.421 (95% CI 0.108 to 1.638) 
p=0.21 indicating that group selection did not contribute to a higher risk of falls. 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
 
Table 18. Adverse Events 
 
System 
 
Vitamin K 
 
Placebo 
Cardiovascular 6 
(cellulitis, varicose ulcers, leg 
cramps & poor circulation) 
5 
(TIA not admitted to hospital, 
lower limb circulatory problems) 
Pain 4 
(knee, back & shoulder) 
3 
(leg, abdominal pain) 
Gastro-Intestinal 
disturbances 
10 
(nausea/vomiting, swallowing 
difficulties, dry throat, abnormal 
liver function results) 
5 
(weight loss, Oral thrush,  
gastric ulcer, dry mouth) 
Postural symptoms 
 
2 
(Labyrinthitis & dizzy spells) 
2 
(dizzy spells) 
Falls / 
musculoskeletal 
17 
(not requiring medical attention) 
7 
(not requiring medical attention) 
Infections 6 5 
TOTAL Events: 42 27 
 
TIA: transient ischaemic attack. GI: Gastrointestinal 
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3.5   Adherence to medication 
Adherence to medication was assessed by tablet counting at each study visit with 
>80% of medications taken deemed as ‘adherent’. Of the 78 participants who 
returned for the three month visit 33/39 (83%) of the vitamin K group and 31/39 
(78%) of the placebo were categorised on this basis as ‘adherent’. At the end of the 
study all study medication containers were returned and tablet counting categorised 
35/38 (92%) of the vitamin K group and 37/39 (95%) of the placebo group adherent 
to medication giving a very good overall adherence of 94%. 
 
Dropout during the six month follow-up period was very low; 77/80 (96%) of 
participants completed the final follow-up visit. 
 
3.6   Analysis  
All results were calculated using only data collected at each time point for each 
participant with missing values not included. To test if this missing data had had an 
effect on the results of the vascular outcome measures missing values were imputed 
using age; sex; baseline SBP, 6 month SBP, baseline FMD and 6 month FMD.  
When results of the five sets of imputations were combined the adjusted between 
group difference in FMD at 6 months was -0.3% (95%CI -1.4 to 0.8), no change 
from the original results. It is unlikely therefore that had the data been complete it 
would not have resulted in a change of outcome. 
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4. DISCUSSION AND CONCLUSION 
4.1   Summary of main findings 
This randomised controlled trial found that six months of vitamin K supplementation 
did not improve endothelial function of the brachial artery measured by FMD when 
compared to placebo administration. In addition, no significant differences were seen 
in PWV, carotid IMT, BNP, CRP or in physical function as measured by hand grip 
strength and SPPB between the two groups. Arterial stiffness, as measured by PWV, 
was non-significantly lower in the vitamin K group at 6 months, after adjustment for 
baseline values.  
 
Adherence to the study medication was high, and dropout rates were low despite the 
study group comprising older people with significant multimorbidity.  
 
Missing data was low at <10% however multiple imputation analysis was carried out 
confirming that missing values did not have an effect on the overall results. 
 
Recruitment and Retention 
The study met its aim to recruit 80 older people with a history of vascular disease 
and achieved excellent retention. Several factors were likely to have contributed to 
this: 
 All participants were recruited via their GP surgeries and it was evident from 
the initial telephone contact that all were aware of their vascular history and 
motivated to try an intervention with the potential to reduce their risk of a 
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vascular event. Most of the participants (90%) had a diagnosis of 
hypertension, and awareness of this diagnosis may have prompted people to 
volunteer for a study in which a simple vitamin supplement might reduce 
their vascular risk. 
 The group of patients enrolled in this trial were relatively fit compared to 
those enrolled in some other trials to improve health in older people 
(156;157)
  
as evidenced by their superior SPPB and grip strength measurements. They 
were prepared to travel to and from hospital for outcome visits, something 
which may have discouraged frailer, less able people from taking part. 
Another factor that may have improved retention in the study was that the 
burden of the study visits was low, with a requirement to attend three visits of 
between 1 and 2 hour duration over a 6 month period with a request to take 
only one extra medication capsule per day. Given the daily medication 
burden of the participants (median 5 medications per day) this did not deter 
the majority of volunteers from entering the study with only eleven choosing 
not to attend the screening visit following the initial telephone contact. 
 Approximately 25% of the older population in the UK take nutritional 
supplements 
(158)
. Several participants acknowledged that they were 
motivated to participate because the study involved a vitamin rather than a 
medicinal product with potential of side effects; this may have made the 
process of recruitment easier. This factor, along with the prospect of having 
vascular assessments which would not be routinely offered on the NHS was 
also anecdotally expressed as a positive aspect of participation for many of 
those who consented.  
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Baseline Measurements 
There were no significant differences at baseline between groups in the primary 
outcome of FMD or in any of the secondary outcome measurements except for the 
PWV scores. Measurement of maximum reactive hyperaemia resulted in a 1% 
difference between the groups at baseline, and although this did not reach statistical 
significance, this difference was potentially important in interpreting the analyses as 
calculating the change score between baseline and 6 months can be misinterpreted if 
correlation between these two scores is low. 
 
Ninety per cent of participants had a diagnosis of hypertension and antihypertensive 
treatment was widely prescribed. This was reflected in the high mean baseline BP of 
145/83 which although higher than the 140/90 target set for younger age groups, was 
below the 150/90 target set for patients aged 80 years and older 
(159).
  
  
A total of 43/80 (53%) of the participants scored > 10 on the SPPB which has a 
maximum score of 12, while the median score of 9 (IQR3) would indicate that the 
participants were located within the minimal limitation range (8 – 10) and are thus 
among the most independent of this population 
(160)
. The vitamin K group were noted 
to have a lower baseline score than placebo with 15/40 (38%) within the minimal 
limitations range compared to 21/40 (53%) in placebo. This was reflected in the fact 
that more of the vitamin group required a walking aid to mobilise and also had a 
lower recorded grip strength.  
 
 
 
107 
 
4.2   Significance of findings  
Primary Outcome 
This study found that vitamin K did not improve vascular function in older people 
with vascular disease as measured by endothelial function. There was no change in 
FMD of the brachial artery in either 3 or 6 month follow-up outcome measurements. 
There are several possible explanations for this finding.  
I. The sample size was too small. The study was powered to detect a 2% 
absolute change in FMD given a standard deviation of 3% based on previous 
studies carried out with diabetic and stroke patients 
(81;161)
. The 95% CI for 
the 0 v 6 months change score analysis had 0.3% as the upper limit. This 
makes it highly unlikely that a real effect of 2% improvement in FMD would 
have been missed.  
II. Improvements were masked by ceiling effects. The baseline measurements 
recorded in this study were higher than average seen in those with vascular 
disease in the Framingham study, and were higher than those previously 
measured in our laboratory in patients with isolated systolic hypertension 
(162)
 
and stroke  
(81)
 using the same protocol and equipment. However, baseline 
FMD was considerably lower than that seen in healthy volunteers; a cut off of 
10.4% has been suggested by some researchers indicating normal artery 
function thus it is unlikely that ceiling effects can explain the lack of 
improvement seen. Furthermore, both groups improved by 1 to 1.5% over the 
6 month study period.  
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III. The dose of vitamin K was insufficient. Participants received 100 µg/L 
Vitamin K2 (MK7 subtype) daily. The current RDI for vitamin K is 80 µg/L 
but this is based purely on the role vitamin K has on the clotting mechanism. 
Studies examining the relationship between vitamin K and CHD have used 
Food Frequency Questionnaires to identify daily intake however this study 
supplemented the diet 
(163)
. Despite the evidence linking vitamin K to 
vascular health it is not yet clear if it can reverse existing vascular damage or 
existing calcification and if so in what the optimum dosage to achieve this 
would be. This study administered the current recommended dose to a 
population regarded as having an intake well below the recommended daily 
intake 
(164)
 and which is currently available to buy over the counter. No upper 
limit for vitamin K has been set and evidence pertaining to vitamin K1 has 
indicated that 1mg or more may be required to maximally carboxylate 
Osteocalcin and Matrix Gla Protein  
(165)
 . Thus potentially higher doses 
might need to be administered in order to achieve an effect as seen in post-
menopausal women recruited to the ECKO study who received 5 mg of 
vitamin K1  
(166)
 where circulating blood vitamin K levels were ten times 
higher in the intervention group compared to placebo.        
IV. The 6 month study duration was too short. A 6 month study duration may not 
have been sufficiently long to detect changes in the vascular markers 
selected. Calcification of blood vessels is a process which has developed over 
many years and intervention with vitamin K may require to be delivered over 
a much longer time period to alter this as shown in previous studies. FMD has 
shown improvement in a few weeks for several treatments such as vitamin D 
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(81)
 and  allopurinol 
(167)
. However if effects of vitamin K are not on 
endothelial function but solely on calcification this would fit with the results 
found in this study. Invasive methods such as plethysmography 
(81) 
have also 
been used to  assess improvement in endothelial function 
(168;169)
, however 
Mullen et al were unable to detect a treatment effect of daily doses of  
enalapril after 24 weeks and concluded that brachial FMD may have  been 
unable to detect improvement due to the complex nature of  vascular disease 
in diabetes mellitus 
(170)
 . 
V. The target population was wrong. The inclusion criteria were designed to 
select participants diagnosed with a wide range of vascular disease. The 
failure of the study to improve vascular function may have been because the 
wrong cohort was selected. Vascular calcification develops over many years 
and it may be that intervention is required at a much earlier stage of the 
disease process i.e. before arthrosclerosis or vascular calcifications are 
established. This group of participants clearly had a high level of physical 
function for their age group and their baseline vascular measurements were 
reasonably good, another explanation is that they may not have had sufficient 
disease severity to show a significant difference in the study period. 
 
Secondary Endpoints 
Arterial stiffness and reflectivity: PWV and Alx were used to measure arterial 
stiffness and reflectivity. The vitamin K group showed a small improvement at six 
month follow-up while the placebo group deteriorated slightly but neither were 
significant. The small but gradual improvement noted in PWV over the study period 
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suggests there may be potential for further improvement if the intervention was to be 
given over a longer period of time. This would be true especially if the improvement 
was due to a reduction in calcification in the arteries which has taken many years to 
develop.  
 
Only a small, non-significant reduction in AIx was seen. However this measure is 
shown to have greater validity in younger populations where changes with 
interventions have been noted rather than improvements in PWV 
(74)
.   
 
No change was detected in the thickness of the intima and media of the carotid artery 
over the duration of the study period. Although previous studies have used changes 
in carotid IMT as a surrogate endpoint for determining the success of interventions 
such as those that lower the levels of low-density lipoprotein cholesterol 
(171)
 it may 
have simply been the wrong tool for this study. It may also be that the 6 month time 
point may have been too short for any potential changes to occur. Previous studies 
have varied in duration with some taking up to 4.5 years before improvements in 
IMT were noted 
(172)
. Atherosclerosis is a process requiring many years to progress 
and a six month follow-up may well have been insufficient to detect improvement. 
This is especially likely in this study population with a mean baseline measurement 
of 0.08cm when values of 0.09  0.26 have been identified in older people without 
vascular disease.  Carotid IMT measurement is frequently chosen as an outcome 
measure because of its quantitative value and high reproducibility. However, given 
that the mean normal change over one year is between 0.010mm and 0.012mm, a 6 
 
 
111 
month study duration may have been insufficient to show any statistically significant 
change.   
I. Markers of vascular prognosis: As with arterial stiffness and reflectivity none 
of the markers chosen to assess vascular prognosis changed over the study 
duration. BNP, blood pressure, total cholesterol, HDL cholesterol, or LDL 
cholesterol remained unchanged. The median BNP was relatively low in the 
study population therefore it may have been difficult for any intervention to 
have further reduced the levels.  
II. Markers of inflammation: The results of the CRP blood test followed a 
similar pattern to the other outcome measures with no significant difference 
noted. Median baseline measurements of 1.8 (3.3) shown in the vitamin K 
group  indicated that this group of participants were not identifiable as being 
at particularly  high risk and therefore it would have been difficult for the 
intervention to have reduced this level. It is also possible that although 
vitamin K has been shown to reduce inflammation in vitro 
(173)
  the 
mechanisms by which vitamin K influences biomarkers of inflammation are 
not known and it may be that vitamin K does not affect inflammation directly 
but by an alternative anti-inflammatory mechanism. 
III. Markers of physical function: A change of 0.54 on the SPPB would have 
been required to identify a small change in physical function, but this did not 
occur in either group. Previous studies have shown that alternative measures 
such as the 400 metre walk test may be a better outcome measure in high 
functioning patients 
(174)
. As with the vascular and inflammatory markers the 
markers of physical function were relatively good at baseline. While the 
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vitamin K group were identified as less physically able than the placebo 
group (grip strength 26.2kgs vs. 29.1kgs), the overall physical functioning of 
all the participants was particularly good given their age and medical history.   
It may be that the potential for this group of relatively fit and active 
individuals to improve significantly over such a short duration period was 
low or that again a higher dose of vitamin K was required to have an effect on 
muscle function.  No direct link has yet been made between muscle function 
and vitamin K and given that no improvement in vascular health was 
identified in this study, positive effect on muscle was unlikely. 
 
Adherence 
Non-adherence to medication can be a major problem with older people often due to 
sensory deficits, cognitive problems and complex regimes as well as the occasional 
belief that the medication will not in fact improve health. It has been estimated that 
adherence for chronic disease averages only 50% 
(175)
 and  non-adherence to 
medication contributes to around 10% of hospital admissions. 
(176)
 Adherence to 
medication in clinical trials of participants receiving treatment for  chronic disease 
varies between 43 and 78% 
(177)
.   
 
Adherence to medication was assessed by tablet count at the two subsequent study 
visits. The 94% overall adherence rate found in this study was similar to that of a 
previous study of vitamins in older community dwelling adults 
(178)
. Serum vitamin K 
levels were checked at baseline and 6 months with the rise in levels shown in the 
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intervention group giving some evidence that the medication was not just removed 
from the bottle, but was actually ingested. 
 
Adverse Events 
More falls were identified in the vitamin k group compared to placebo (17 vs. 7).  Of 
note however, the vitamin K group appeared to be at higher risk of falls than the 
placebo group because of a higher (but non-significant) baseline incidence of 
osteoarthritis, walking aid usage and isolating personal home circumstance.  
 
Also worth consideration is that although a higher incidence of adverse events 
occurred in the vitamin K group this may be attributable to the overall reduced 
functioning ability and increased dependence level of the intervention group   
compared to the placebo group as evidenced by the baseline physical outcome 
measures. The median total medications intake of the vitamin k group was also 
greater (8 vs. 5) suggesting a greater presence of co-morbid disease which may also 
have accounted for the events recorded.  Given these between group differences at 
baseline logistic regression was carried out which concluded that group selection was 
not a significant indictor of falls risk. 
 
4.3   Strengths and Weaknesses 
Strengths 
 The study had a number of notable strengths. It was run as a parallel group, 
randomised controlled trial where both the participants and investigator 
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remained blind to treatment. All outcome measurements, entry of data and 
subsequent data analysis were performed by one single trained investigator 
which eliminated inter-observer variation. Full analysis was performed prior 
to breaking the treatment code which eliminated expectation bias. The 
treatment period was of six months duration, considered to be reasonable 
time for study medication to have affected the preliminary and outcome 
measurements which were collected at three time points throughout the 
duration of the study following the protocol and as per SOPs. 
 A wide range of differing vascular markers were selected as outcome 
measures covering vascular stiffness and calcification. All measures have 
been widely used in clinical research and used previously in similar trials 
within the department and were highly acceptable to participants as 
evidenced by the low drop out rate. 
 The study recruited persons over the age of 70 years, a relevant group of 
participants as vascular disease is more prevalent in later life. 
 Recruitment and retention to the study was excellent with recruitment 
completed within the target timescale and 77/80 (96%) participants 
competing all three study visits.  
 Adherence to study medication was higher than usually found in clinical trials 
especially those targeting older people providing reassurance that the 
negative findings cannot be explained by participants not taking the drugs. 
Weaknesses 
 No stratification was carried out at baseline resulting in baseline differences 
between the groups. More of the vitamin K group required walking aids 
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which may have contributed to the excess of falls which occurred in this 
group. The difference in primary outcome at baseline, although insignificant, 
made analysis more complicated than if both groups had been ideally 
matched and potentially biases the PWV and the adverse event data. 
 People who volunteered were relatively fit and functionally independent. The 
findings therefore apply only to this group. A further trial would be necessary 
to determine whether the results would be different in a frailer group. 
 Follow-up was at three and six months. Other intervention studies, e.g. the 
MARS study have shown that a longer period of intervention is required in 
order for any vascular calcification to regress. The MARS study found that 
while lipid lowering drugs reduced progression of carotid IMT it was not 
until the end of the first year of treatment that any significant reduction was 
detected 
(179)
. Antihypertensive drugs have also been noted to have success in 
producing significant decreases in carotid IMT. These studies which included 
the drugs Amlodipine 
(180)
, and Ramipril 
((172)
 varied in length between 48 
months to 4.5 years duration before a significant reduction  or decrease in 
progression was identified in carotid IMT.   
 Dose was set at baseline with the intervention group receiving a fixed dose of 
vitamin K. Comparison with further groups receiving a higher dose of 
vitamin K could have been made to determine the dose response effect but 
this would have increased the size, complexity and cost of the trial. 
 The choice of outcomes might not have been best suited to detecting change 
within the recruited population. Many physical function tools exists however 
and while the SPPB and grip strength are simple effective measures which 
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have been widely used in older populations, they were not sensitive to the 
effect of vitamin K. 
 The 6 hour fast prior to study visits may have been insufficient to ensure 
dietary vasoactive substances did not influence results while all participants 
were asked to take their normal medications including any antihypertensives 
if prescribed on the morning of each for their assessment visits.  Although 
these pre-visit preparation instructions may have in some way influenced 
results of vascular assessments, especially the FMD and PWV results, it 
could be argued that had participants been asked to omit regular medication 
or fast for a longer period this may also have influenced results thus a 
consistent approach was taken across the study. 
 Although FMD, carotid IMT and PVW are widely used validated techniques, 
which once learnt, have good inter- and intra-operator reproducibility this 
was the first study using these techniques for the investigator, resulting in a 
lack of validation data. Despite training and repeated practice showing good 
reproducibility prior to participant recruitment this lack of experience may 
have affected the collection of data. 
 PVW can be measured using several different artery sites with carotid-radial 
and carotid-femoral being the two most commonly used in clinical studies. 
This study measured carotid-radial PWV as it was felt that this would be less 
of a physical burden on the older patients being recruited. Despite this site 
being validated and used in other published clinical trials it does not follow 
the 2007 European Society of Hypertension guidelines, which set carotid-
femoral as the gold standard measurement of arterial stiffness. 
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 It was not possible to collect data on every participant for all outcome 
measurements at each of the 3 study time points. This missing data, although 
totalling less than 10% of the overall total, may have had some affect on the 
results. It is however unlikely that missing data made a significant difference 
to the overall results.  
 
4.4 Conclusion 
This study showed that supplementation of the diet with the daily recommended dose 
of vitamin K did not improve vascular health or physical function in older people 
with established vascular disease; this despite excellent adherence to medication and 
a low dropout rate from the study. 
 
Osteocalcin, Matrix Gla protein, and Gas6 have all been identified as proteins which 
are dependent on the presence of vitamin K. It is thus it is entirely possible that 
increased intake of vitamin K could exert beneficial effects on vascular health, 
particularly with respect to vascular calcification which is highly prevalent in older 
people and leads to stiff arteries and high blood pressure. 
 
Previous studies have shown that higher intake of vitamin K is associated with lower 
serum concentrations of undercarboxylated osteocalcin, which in turn is associated 
with lower bone mineral density 
(38;39)
. Animal studies  have shown that the reversal 
of calcification of the arteries is possible, while in humans uncarboxylated MGP has 
been identified as being present in calcified regions of the vasculature 
(38)
. A previous 
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study of post-menopausal women identified a link between low levels of vitamin K 
and atherosclerotic calcification in the abdominal aorta 
(181) 
 providing strong 
evidence to study the effect on vascular calcification in this high risk group 
(182)
. 
 
Although no improvement was noted in the primary or the majority of the secondary 
outcome measures a small improvement in arterial stiffness was identified at 6 
months. This small but gradual reduction in PWV at 6 months may suggest that 
treatment with vitamin K over a longer period of time might indeed provide further 
benefit.  These are the results which would have been expected if indeed vitamin K is 
acting via inhibition of calcification, rather than directly to improve endothelial 
function.  
 
This was the first study testing the ability of vitamin K to improve vascular health in 
older people. However those who volunteered for the study were relatively fit and 
healthy given their age and the findings therefore apply only to this group and a 
further trial would be necessary to determine whether the results would be different 
in a frailer group.  
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5.   FUTURE RESEARCH 
The majority of the study population had hypertension and although vitamin K did 
not improve vascular calcification in this particular patient group investigation of the 
role of vitamin K in other populations may be worthwhile.  
 
The dose required or time frame necessary to improve vascular function remains 
uncertain, with the key question of whether the in vitro, animal data and 
observational data translate into clinically important effects in humans.  Further 
research should address the fact that this study only evaluated a single dose of 
vitamin K and investigate the outcome for higher vitamin K doses given over a 
longer period of time.  
 
The reporting of adverse events, although higher in the vitamin K group, was very 
unlikely to be attributable to the supplementation in this study. However any future 
work in this field, particularly if higher doses are to be administered, should ensure 
adverse events are monitored closely. 
 
 
5.1 Vitamin K and Cardiovascular Health 
The vascular disease process has been shown to develop in arteries many years 
before the symptoms emerge. Giving vitamin K to a younger group of people may be 
a better approach.  
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The close links between both diabetes and CVD and between chronic kidney disease 
and CVD are well known but both these groups also develop medial calcification. 
This merits further exploration of the effect of vitamin K in future trials, as this 
pattern of vascular calcification differs from the atherosclerotic calcification pattern 
typically seen in older patients. 
 
5.2 Vitamin K and Neuromuscular function and Bone 
Health 
Given about a third of all people aged over 65 fall each year  (equivalent to over 
three million people), 
(183)
 and the available evidence reports that those with lower 
circulating vitamin K levels sustain higher hip fracture rates 
(184)
  research should aim 
to encapsulate both these disease processes. A study of older people with a history of 
falls would involve participation from frailer, less independent people. This may 
offer the potential to exhibit change both physically as well as functionally, which 
was not possible within the group used for this study. 
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Appendix 2: Patient Information Letter 
GP Practice 
Headed paper 
 
Dear Mr/ Mrs XYZ, 
 
Research Project: Vitamin K to improve markers of vascular 
health in older people with vascular disease  
– a randomised controlled trial 
 
Our practice is helping researchers at the University of Dundee 
with this research study, which is funded by Chest Heart and 
Stroke Scotland.  
 
People with high blood pressure, diabetes, previous heart disease 
or stroke often have stiff arteries, which can increase the chances 
of further heart and blood vessel problems. Dr Miles Witham and 
his team at the University of Dundee are testing whether taking a 
vitamin K supplement for 6 months can reduce the stiffness and 
improve the health of arteries.  
 
Taking part would involve taking a single tablet of either vitamin K 
or a placebo (dummy) for 6 months, and visiting Ninewells 
Hospital on three occasions to have tests on your arteries, 
strength and balance. 
 
We are writing to you because you are over the age of 70 and this 
study may be suitable for you to take part in. 
 
Please complete the attached reply slip and return to me in the 
enclosed stamped addressed envelope. If you are interested, I will 
pass your name to the study team in Ageing and Health at 
Ninewells Hospital, Dundee, and the study team will get in touch 
with you to provide more information. 
 
With best wishes 
GP 
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Appendix 4: Patient Reply Slip 
 
 
PRACTICE HEADER 
 
 
Research Project: Vitamin K to improve markers of vascular 
health in older people with vascular disease  
– a randomised controlled trial 
 
 
Please only complete and return if you would like for information 
about the study 
 
Name……………………………………………………………..………… 
 
Address……………………………………....…………………...……….. 
 
………….………………………...………..… Postcode ………...…....... 
 
Telephone number……………....……  
 
Best time to contact………..…. 
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Appendix 3: Patient Information Sheet 
 
PARTICIPANT INFORMATION SHEET 
 
Can Vitamin K improve markers of vascular health 
and physical function in older people with vascular 
disease? 
 
 
My name is Roberta Fulton and I am required to undertake a 
project as part of my MSc course at the University of Dundee. I 
invite you to take part in the following study however, before you 
decide to do so, I need to be sure that you understand firstly why I 
am doing it, and secondly what it would involve if you agreed.  I 
am therefore providing you with the following information. Please 
read it carefully and be sure to ask any questions you might have, 
and, if you want, discuss it with others including your friends and 
family.  I will do my best to explain the project to you and provide 
you with any further information you may ask for now or later.  
You do not have to make an immediate decision. 
 have to make an immediate d 
Why are we doing this study? 
Vitamin K has long been known to be an important factor in 
maintaining good bone health but recent research has shown that 
it may also have a beneficial effect on our blood vessels. 
Unfortunately daily intake of vitamin K is below the recommended 
dose for the majority of adults in the UK, this low level of vitamin K 
has been linked to stiffening of the arteries, which in turn may 
cause high blood pressure, heart attacks and strokes, especially 
in older people. 
We therefore want to test if giving a daily dose of vitamin K to 
people with either high blood pressure or previous cardiovascular 
disease (stroke, heart attack, angina, or hardening of the leg 
arteries) will improve the function of the blood vessels as well as 
general fitness. 
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Why have I been chosen? 
You have been chosen to take part in the study because you are 
over the age of 70 years and have had a cardiovascular disease, 
high blood pressure or diabetes. 
 
 
Do I have to take part? 
It is up to you to decide. Participation in this study is entirely 
voluntary and you are free to refuse to take part or to withdraw 
from the study at any time without having to give a reason and 
without this affecting your future medical care or your relationship 
with medical or nursing staff looking after you.  
 
What will happen to me if I take part? 
 
The study takes 6 months in total to complete. 
The study is of randomized, doubled blind design. This means 
that you will be asked to take a capsule by mouth once a day. 
This will either contain vitamin K, or a placebo (dummy) 
medication. The one that you will be given is decided in a random 
way (a bit like tossing a coin, but done by a computer). Neither 
you nor the research team will know which tablet you are taking 
until after the study is finished. This means that the results of the 
study cannot be influenced by you or the researchers knowing 
what you are taking.  
 
You will be asked to come to Ninewells Hospital in Dundee on 
three occasions over 6 months for study visits. We can provide a 
taxi to transport you to Ninewells and back for each visit or we can 
reimburse your travel expenses should you choose to make your 
own travel arrangements. 
 
After making sure that you are suitable to participate in the study 
and obtaining your consent we will ask you to undergo an 
assessment which will last between one and two and a half hours. 
At each visit we will do the following: 
 
 We will measure your blood pressure while you are lying 
down and then when you stand up. 
 
 We will ask permission to take a blood test (about two 
tablespoons of blood will be taken). Blood samples will be 
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stored and analysed at the end of the study. We will also 
ask your permission to store the blood samples for a period 
of 10 years after the end of the 20 month study, so that we 
can run further tests on the blood in the future. We will not 
test any of your blood samples for genetic testing either 
now or in the future. 
 
 You will be asked to do some mobility tests including - 
standing tests, balance tests and a test to measure your 
hand grip strength. 
 
 We will then measure how one of the blood vessels in your 
arm functions (brachial artery ultrasound), this will show 
any evidence of hardened (stiff) arteries. This is done using 
an ultrasound machine. To see how stiff the blood vessel is 
we need to look at how it responds to a short period of 
having the circulation to the forearm blocked. A blood 
pressure cuff will be placed below your elbow and we 
measure the heart tracing (ECG) at the same time. We will 
then take an ultrasound measurement of the artery above 
your elbow. This involves placing a probe gently on the 
skin above the elbow. We will then inflate the cuff to cut off 
the circulation to the forearm for a period of 5 minutes. This 
can be a little uncomfortable, just like if you lie on your arm 
when you are asleep. After 5 minutes we will release the 
blood pressure cuff and take another measurement of the 
artery above the elbow. We will also scan the artery in your 
neck using the ultrasound probe. This will all take about 30 
minutes 
 
 We will test how elastic the blood vessels are in your neck, 
wrist and thigh by using a small pencil-like device placed 
over the blood vessel to measure your pulse. At the same 
time, the electrical activity of your heart will be monitored 
with a heart tracing. This will take about 10 minutes. 
 
 We will issue your study tablets 
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At 3 and 6 months we will ask you to pay us further visits where 
we will repeat some or all of the above tests – see the summary 
below.   
 
 
 
Summary of tests: 
 
Baseline visit: Sign consent form. 
Blood test, lying and standing blood pressure, artery tests, heart 
tracing, standing tests, balance tests and tests to measure your 
hand strength. Receive  medication. 
 
Time: 2 hours 
 
3 month visit: Lying and standing 
blood pressure, artery tests. Receive  medication. 
 
Time: 1 hour 
 
6 month visit: Blood test, lying and standing blood pressure, artery 
tests, heart tracing, standing tests, balance tests and tests to 
measure your hand strength. 
 
Time: 90 minutes 
What is being tested? 
Vitamin K is a natural substance which is present in everyday 
foods such as leafy vegetables. Many people in Scotland don’t get 
as much vitamin K as recommended. We wish to test whether or 
not giving a daily dose of vitamin K can improve the function of 
blood vessels and improve general fitness. 
 
Will taking part in the study affect your usual care? 
We will not alter any of your medication or interfere with your 
treatment in any way however we would ask you not to purchase 
or take any vitamin K independently while on the study. 
 
What are the possible discomforts, risks and side effects? 
This dose of vitamin K has been used before and is known to be 
safe but as with all medications there is a small possibility of side 
effects. If you experience any side effects of sickness, diarrhoea, 
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dizziness or bruising, please report them to us as soon as they 
arise.  
 
Having blood taken can cause some bruising. The blood pressure 
cuff causes mild discomfort to some people. 
 
What happens if something goes wrong? 
This is very unlikely, but if something does go wrong then the 
University of Dundee has a scheme which could provide 
compensation, if appropriate. 
If you believe you have been harmed in any way by taking part in 
this research, the normal NHS complaints mechanism would also 
be available to you. To register a complaint against the NHS in 
Tayside, or to receive more information, contact: 
  
 Complaints and 
Advice Team 
 Level 7, Ninewells 
Hospital and Medical School 
 Dundee DD1 9SY. 
Free-phone 0800 027 5507 
 
Will my GP know about this research project? 
If you agree to take part, your GP will be informed of this. 
 
Will my taking part in this study be kept confidential? 
All the identifiable data, samples or information collected with your 
consent will be retained and used in the study. They will be kept 
strictly confidential. The information will be kept in a locked room 
and held on a secure computer, with your name and other 
identifying details removed. Should you choose to withdraw from 
the study no further data or samples would be collected. Only the 
researchers involved in the study will have access to the 
information.  We will keep the information for at least 15 years.  
  
What will happen to the results? 
The results will be examined by the researchers who have 
organised the study and a short report will be produced.  You will 
not be identified in this report.  The results will be shared with the 
funder for the study (Chest Heart and Stroke Scotland). The 
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results will then be published in scientific journals. Again, you will 
not be identified in any journal articles. 
 
Who is organizing and funding this research? 
The study has been organised by Dr Miles Witham and Professor 
Marion McMurdo (Ageing and Health, University of Dundee), Dr 
Faisel Khan and Dr Sandy Hill (Vascular Medicine, University of 
Dundee). The study is funded by Chest Heart and Stroke 
Scotland. 
 
Who has reviewed the study? 
Tayside Research Ethics Committee, which has responsibility for 
scrutinising proposals for medical research on humans in Tayside, 
has examined the proposal and has raised no objections from the 
point of view of medical ethics.  It is a requirement that your 
records in this research, together with any relevant medical 
records, be made available for scrutiny by monitors from NHS 
Tayside and the University of Dundee whose role it is to check 
that research is properly conducted and the interests of those 
taking part are adequately protected. 
 
 
Thank you for reading this Information Sheet and considering 
taking part in this study. 
 
 
For further information contact: 
Mrs Roberta Fulton - Research Nurse on telephone 01382 
632436 or email r.l.z.fulton@dundee.ac.uk 
 
Dr Miles Witham - on telephone 01382 632436 or email 
m.witham@dundee.ac.uk 
 
 
Dr Jacob George - Department of Clinical Pharmacology, 
Ninewells Hospital.  Email j.george@dundee.ac.uk 
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Appendix 5: Consent Form 
Study Number: 11/ES/0009 
Patient Identification Number for this trial:  
CONSENT FORM v1.1 (05/09/2011)  
Title of Project: The KIMVASC study: vitamin K to improve markers of 
vascular health and physical function in older people with vascular 
disease  
– a randomised controlled trial 
 
Name of Researcher: Dr Miles D Witham                                          Please initial box 
 I confirm that I have read and understood the information sheet dated 05/09/11 
(version 1.1) for the above study.  I have had the opportunity to consider the 
information, ask questions and have had these answered satisfactorily. 
 
 
 I understand that my participation is voluntary and that I am free to withdraw at 
any time without giving any reason, without any medical care or legal rights being 
affected. If I withdrawn I understand any data already collected will be retained 
and used in the study. 
 
 
 
 I understand that relevant sections of my medical notes and data collected during 
the study may be looked at by representatives from NHS Tayside and University 
of Dundee, where it is relevant to my taking part in this research.  I give 
permission for these individuals to have access to my records. 
 
 
 I agree to my GP being informed of my participation in the study. 
 
 
 I agree to the storage of my leftover blood samples for use in future research. 
 
 
 I agree to take part in the above study.  
________________________        _______________     ____________________ 
Name of Participant                         Date                           Signature                                
 
 
________________________       ________________    ____________________ 
Name of Peron Taking Consent     Date                            Signature         
                                  
When complete, 1 for participant; 1 for researcher site file; 1 (original) to be kept in 
medical notes  
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Appendix 6: GP Letter 
 
 
/ 
 
Vitamin K to improve markers of vascular health and physical function 
in older people with vascular disease - a randomised controlled trial 
 
Dr XYZ 
Surgery 
 
 
 
Dear Dr  
 
Re: Mr/Mrs ABC, Address 
DOB/CHI: 0000000000 
 
Your patient, Mr/Mrs ABC, has very kindly agreed to take part in the above 
trial.  
 
Participants will receive 6 months of oral vitamin K2 100 micrograms per day 
or placebo. We will provide all of the trial medication while all other 
medications can continue as usual. Both participants and assessors will be 
blinded to the nature of the therapy. We will assess outcomes (endothelial 
function, arterial stiffness, carotid intima-media thickness, physical function, 
strength and balance, blood pressure, B-type natriuretic peptide and C-
reactive protein) at baseline, 3 and 6 months. 
 
Please let us know if you need to consider warfarin therapy over the course 
of the next six months, as vitamin K antagonises the effect of warfarin. 
        
This project has been funded by Chest, Heart & Stroke Scotland. 
 
The study has been approved by the Tayside Committee on Medical Ethics. 
If you have any questions about the study, or if there is any aspect of your 
patient’s healthcare that we can assist you with, please do not hesitate to 
contact us. 
 
Yours sincerely, 
 
 
 
Dr Miles D Witham 
Clinical Senior Lecturer and CSO Clinician Scientist in Ageing and Health 
Tel: 01382 632436  
 
 160 
Appendix 7: Case Report Form  Page 1 
CASE REPORT FORM Visit 1 – (Screening & Baseline visit)    
 
 
 
 
 
Patient Study ID number                             Date of Study Visit 
 
A. Inclusion Criteria 
 
Age 70 and over                     And             at least 1 of following: 
 
Hypertension (as a listed diagnosis)        1 
 
Diabetes mellitus        2                                Myocardial infarction          3 
 
Coronary artery bypass grafting        4       Coronary angioplasty         5 
 
Stroke or TIA          6                                     Peripheral Vascular disease          7 
 
 
 
*IF THE ANSWER IS NO TO ANY OF THE ABOVE, THE PATIENT IS NOT ELIGIBLE TO 
CONTINUE 
IN THE STUDY 
 
B. Exclusion Criteria 
 
Atrial fibrillation        1                 Unable to give written informed consent          3      
 
Taking Warfarin        2             Currently taking Vitamin k supplements           4 
       
Unable to walk without human assistance (walking aids are permitted)          5 
 
Enrolled in another research study          6 
 
*IF THE ANSWER IS YES TO ANY OF THE ABOVE, THE PATIENT IS NOT ELIGIBLE TO 
CONTINUE IN THE STUDY 
 
Informed Consent  
Has written informed consent been obtained for study participation?               Yes 1    /    No 2 
 
 
 
 If yes, date consent signed                                                                 
                                                                DD          /         M M              /        Y Y Y Y 
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                                                             Study ID   
 
 
Demographics  
 
 
 Sex     Male 1     /     Female  2                 
            
                                      
 Living Status:  Own Home 
1  
/
  
Sheltered Housing 
2  
 /   RHE 
3
  /  NH 
4  
/  Living with relative 
5   
 
/ Other  
6 
 
 
If other please specify                                                                      
 
 
Living Alone        Yes 1   /    No   2                             Formal Help at Home       Yes 1    /     No 2  
 
 
 
Smoker      Never 
1    
  
                   Ex 
2
               Approx. number of years smoked                      Date stopped                        
 
                            
Current 
3
        Average number cigarettes per day                     
 
 
 
 
Walking Aid       None 
1 
  /    1 Stick 
2 
   /    2 Sticks 
3  
  /    TWW 
4    
/    ZWF 
5
    /    Other 
6 
 
 
If other please specify                                                                      
 
 
Past Medical History 
 
          Description                                                Date of Diagnosis if known        
 
o Hypertension         Yes 1   /   No 2                                                                      
 
o Previous MI           Yes 1   /   No 2                                                             
 
o Stroke / TIA           Yes 1   /   No 2                                                                                        
 
o Angina                   Yes 1   /   No 2                                                                                                   
 
o CABG / PTCA        Yes 1   /   No 2                                                                                       
 
o Diabetes Mellitus    Yes 1  /  No  2                                                           
 
o P VD                        Yes 1  /  No 2                                                                   
 
o CHF                         Yes 1  /  No 2                                                             
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                                                           Study ID 
 
 
Any Other relevant medical or surgical history?             
                                                           
       Description                                                   Date of Diagnosis if known          Still present 
 
                                                                                                                      Yes
1
 / No
 2 
 
 
                                                                                                                                                                                    
Yes 
1 
/ No
 2 
 
 
                                                                                                                                                                                     
Yes 
1
/ No
 2 
 
 
                                                                                                                                                                                    
Yes  / No
 2 
 
 
                                                                                                                                                                                    
Yes 
1 
/ No
 2  
 
 
                                                                                                                                                                                   
Yes 
1 
/ No
 2 
 
 
                                                                                                                                                                                  
  Yes 
1 
/ No
2 
 
 
                                                                                                                                                                                    
Yes 
1 
/ No
2 
   
 
                                                                                                                                                                                  
 Yes 
1
 / No
2   
 
 
                                                                                                                                                                                   
Yes 
1 
/ No
 2 
 
Vital Signs 
 
Lying Supine Blood Pressure (lying for a minimum of 5 minutes prior to recording)                                                                                                     
                                                                                                                                             
             Reading 1                 Reading 2                    Reading 3          Mean readings of 2 & 3 
 
 
SBP                             mmHg                                mmHg                                        mmHg                                                                 
mmHg               
 
DBP                 mmHg                                                   mmHg                                          mmHg                                                      
mmHg             
 
 
Standing 0 minute   SBP                           mmHg 
 
                               DBP                   mmHg                                       Complaints of dizziness     Yes 
1
  /  No 
2
 
 
 
Standing 1 minute   SBP                           mmHg 
 
                               DBP                   mmHg                                       Complaints of dizziness     Yes 
1
   / No 
2 
 
Standing 3 minutes   SBP                             mmHg 
 
                                  DBP                 mmHg                                       Complaints of dizziness      Yes 
1
 / No
2 
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                                                           Study ID 
 
 
 
Patient fasted for 4 hours?                         Yes 1         No 2 
 
If No, give reason                                                                                                       
    
ECG 
 
Has a 12 lead ECG been recorded            Yes 1         No 2 
 
If No, give reason                                                                                                       
 
 
If yes, does ECG show evidence of atrial fibrillation    Yes 1         No 2 
 
If yes participant unable to continue  
 
Pulse Wave Velocity 
 
Pulse Wave velocity                m/s    Augmentation index (@75%)_________ 
 
Flow Mediated Dilatation 
 
% change in flow following forearm occlusion                  .              % 
 
Carotid  Intima –media thickness  
 
Carotid Artery Scanned -   Right side     /     Left side 
 
Measurement 1   cm 
 
Measurement 2 cm 
 
Measurement 3 cm 
 
Blood test 
 
Blood tests taken for measurement of 
 
C-reactive protein                                       INR                                Plasma mk7           
 
BNP                                                            U&E’s                             Cholesterol 
                                            
 Strength Measures 
 
Grip strength (peak force                                              Kg (record best of 3 - using non 
dominant hand) 
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                                                                   Study ID 
 
 
SHORT PHYSICAL PERFORMANCE BATTERY 
 
1) BALANCE TESTS 
A. Side-by-side-stand                                                               B. Semi-Tandem Stand       
                         
Held for 10 sec                            1 point                                     Held for 10 sec                     1 
point             
Not held for 10 sec                      0 points                                   Not held for 10 sec               0 
points 
Not attempted                              0 points                                   Not attempted                      0 
points                    
  
If 0 points, end Balance Tests and go to                           If 0 points, end Balance Tests 
and go to section D                                                                              section D  
 
C. Tandem Stand                                                                 D. Total Balance Tests score                                      
Held for 10 sec                                    2 points                    (sum points) 
Held for 3 to 9.99 sec                          1 points 
Held for < than 3 sec                           0 points 
Not attempted                                      0 points      
2) GAIT SPEED TEST  
 
Time for 1
st
 Gait Speed Test (sec)                                  Time for 2
nd
 Gait Speed Test (sec) 
 
Time for 4 meters                       .             Sec                Time for 4 meters                       .             
Sec 
 
Aids used             none                     stick                       0ther                                                             
 
Using the shorter of the two times:  
     
If the participant was unable:              0 points   If time is 4.82 to 6.20 sec                 3 points  
 
If time is more than 8.70 sec:             1 points   If time is less than 4.82 sec:             4 points 
 
If time is 6.21 to 8.70 sec:                  2 points 
 
3) CHAIR STAND TEST  
 
Unable to complete or >60 sec:             0 points     Chair stand time 11.20 - 13.69 sec:             
3 points 
 
Chair stand time > 16.70 sec:                1 point       Chair stand time 11.19 sec or less              
4 points 
 
Chair stand time 13.70 to 16.69 sec:            2 points 
 
Total Balance Test   +   Gait Speed Test   +   Chair Stand Test                        
     
                                             Total Score points                  (sum of 3 points above)  
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                                                                          Study ID 
 
 
Falls History 
 
Falls recorded in past 3 months.                            Yes 1                  No 
2 
 
If yes    Number   
 
Details                                                                                                              
 
                                                                                                                          
 
 
 
Study Medication 
 
Medication dispensed                                   Yes 1         No 2 
 
 
Number of tablets dispensed 
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CASE REPORT FORM Visit 2 – (3 months)    
 
 
 
 
 
Patient Study ID number                             Date of Study Visit 
 
 
 
 Has patient taken study medication            Yes 1    /    No 2 
 
If no state reason         ____________________                                                           
 
Count tablets left in bottle.       Yes 1    /    No 2 
 
If action not carried out please state why                                                                    
 
Number of tablets left in bottle 
 
Number of days since last study visit 
 
Have there been any GP appointments since last visit 
 
If yes how many 
 
Have there been any hospitalisations since last visit 
 
If yes how many 
 
Have there been any changes to life circumstances since previous visit? 
 
If yes please detail                                                                                                                 
 
                                                                                                                                               
Medical history update 
 
Has the patient’s medical history changed since previous visit?                        
Yes 1  /  No 2 
 
If yes please detail                                                                                                                 
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                                                                     Study ID 
 
 
Medication  
 
Have there been any changes to the patient's medications since the  
previous visit?                                                                                                     
 
 
Yes 1  /  No 2 
(If yes please detail) 
 
 
 
Adverse Events 
 
Has the patient experienced any adverse events since the previous visit         
Yes 1  /  No 2 
 
If yes please complete a Clinical Trial Adverse Events Form. 
 
Vital Signs 
 
Lying Supine Blood Pressure (lying for a minimum of 5 minutes prior to recording)                                                                                                         
 
 
                                                                                                                                                        
              Reading 1                 Reading 2                    Reading 3           Mean readings 2 & 3 
 
 
SBP                             mmHg                                mmHg                                        mmHg                                                                 
mmHg               
 
DBP                 mmHg                                                   mmHg                                          mmHg                                                      
mmHg             
 
 
Standing 0 minute      SBP                           mmHg 
 
                                   DBP                   mmHg                                   Complaints of dizziness    Yes 
1
 / No 
2
 
 
                                                                                                                                   
Standing 1 minute      SBP                           mmHg 
 
                                   DBP                   mmHg                                 Complaints of dizziness      Yes 
1
 / No 
2 
 
 
Standing 3 minutes    SBP                             mmHg 
 
                                   DBP                 mmHg                                   Complaints of dizziness       Yes 
1
 / No 
2
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                                                                        Study ID         
 
 
Patient fasted for 4 hours?                         Yes 1         No 2 
If No, give reason                                                                                                       
    
 
   
 
 
Pulse Wave Velocity 
 
Pulse Wave velocity                                                         % 
 
Augmentation index (@75%) ____________ 
 
 
 
 
Flow Mediated Dilatation 
 
% change in flow following forearm occlusion                  .              % 
 
 
Carotid  Intima –media thickness  
 
Carotid Artery Scanned -   Right side     /     Left side  
 
Measurement 1                      cm 
 
Measurement 2                      cm 
 
Measurement 3                      cm 
 
Falls History 
 
Falls recorded in past 3 months.       Yes           1                  No           2 
 
If yes    Number   
 
Details                                                                                                              
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CASE REPORT FORM Visit 3 – (6 months)    
 
 
 
Patient Study ID number                             Date of Study Visit 
 
 
 
Has patient taken study medication            Yes 1    /    No 2 
 
If no state reason         ________________________                                                           
 
Count tablets left in bottle.       Yes 1    /    No 2      
 
If action not carried out please state why                                                                    
 
Number of tablets left in bottle 
 
Number of days since last study visit 
 
Have there been any GP appointments since last visit?            Yes 1   /    No 2 
 
If yes how many 
 
Have there been any hospitalisations since last visit? 
 
If yes how many 
 
Have there been any changes to life circumstances since previous visit? 
 
If yes please detail                                                                                                                 
                                                                                                                                          
 
Medical history update 
 
Has the patient’s medical history changed since previous visit?                     
Yes 1    /   No 2 
If yes please detail                                                                                                                 
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                                                              Study ID 
 
 
Medication  
 
Have there been any changes to the patient's medications since the  
previous visit?                                                                                                    
 
Yes 1   /   No 2 
(If yes please detail)  
 
 
Adverse Events 
Has the patient experienced any adverse events since the previous visit        
Yes 1   /   No 2 
 
If yes please complete a Clinical Trial Adverse Events Form. 
 
Vital Signs 
 
Lying Supine Blood Pressure (lying for a minimum of 5 minutes prior to recording)                                                                                                         
 
 
                                                                                                                                                        
              Reading 1                 Reading 2                    Reading 3              Mean readings 2 & 3 
 
 
SBP                             mmHg                                mmHg                                        mmHg                                                                 
mmHg               
 
DBP                 mmHg                                                   mmHg                                          mmHg                                                      
mmHg             
 
 
Standing 0 minute      SBP                           mmHg 
 
                                   DBP                   mmHg                                    Complaints of dizziness   Yes 
1
 / No 
2
 
 
                                                                                                                                   
Standing 1 minute      SBP                           mmHg 
 
                                   DBP                   mmHg                                   Complaints of dizziness    Yes 
1
 / No 
2 
 
 
Standing 3 minutes    SBP                             mmHg 
 
                                   DBP                 mmHg                                    Complaints of dizziness     Yes 
1
 /  No 
2
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                                                          Study ID 
 
 
 
Patient fasted for 4 hours?                         Yes 1         No 2 
 
If No, give reason                                                                                                       
 
 
 
Pulse Wave Velocity 
 
Pulse Wave velocity                                                         % 
 
Augmentation index (@75%) ____________ 
 
Flow Mediated Dilatation 
 
% change in flow following forearm occlusion                  .              % 
 
Carotid  Intima –media thickness  
 
Carotid Artery Scanned -   Right side     /     Left side 
 
Measurement 1                    cm 
 
Measurement 2                    cm 
  
Measurement 3                    cm 
 
 
Blood test 
 
Blood tests taken for measurement of 
 
C-reactive protein                      Cholesterol                  
 
BNP                                           Plasma mk7                    
 
                                            
Strength Measures 
 
Grip strength (peak force                                               Kg (record best of 3 - using non 
dominant hand) 
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                                                                          Study ID 
 
 
SHORT PHYSICAL PERFORMANCE BATTERY 
1) BALANCE TESTS 
A. Side-by-side-stand                                                               B. Semi-Tandem Stand       
                         
Held for 10 sec                            1 point                                     Held for 10 sec                     1 
point             
Not held for 10 sec                      0 points                                   Not held for 10 sec               0 
points 
Not attempted                              0 points                                   Not attempted                      0 
points                    
  
If 0 points, end Balance Tests and go to                           If 0 points, end Balance Tests 
and go to section D                                                                              section D  
 
C. Tandem Stand                                                                       D. Total Balance Tests score                                      
Held for 10 sec                                    2 points                                       (sum points) 
Held for 3 to 9.99 sec                          1 points 
Held for < than 3 sec                           0 points 
Not attempted                                      0 points      
 
2) GAIT SPEED TEST  
 
Time for 1
st
 Gait Speed Test (sec)                                  Time for 2
nd
 Gait Speed Test (sec) 
 
Time for 4 meters                       .             Sec                Time for 4 meters                       .             
Sec 
 
Aids used             none                     stick                       0ther                                                             
 
Using the shorter of the two times:  
     
If the participant was unable:             0 points             If time is 4.82 to 6.20 sec                 3 
points  
 
If time is more than 8.70 sec:             1 points            If time is less than 4.82 sec:             4 
points 
 
If time is 6.21 to 8.70 sec:                  2 points 
 
3) CHAIR STAND TEST  
 
Unable to complete or >60 sec:             0 points     Chair stand time 11.20 - 13.69 sec:             
3 points 
 
Chair stand time > 16.70 sec:                1 point       Chair stand time 11.19 sec or less              
4 points 
 
Chair stand time 13.70 to 16.69 sec:            2 points 
 
Total Balance Test   +   Gait Speed Test   +   Chair Stand Test                        
Total Score points                                           (sum of 3 points above) 
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                                                              Study ID 
 
 
Falls History 
 
Falls recorded in past 3 months.                        Yes 1       /        No 
2
 
 
If yes    Number   
 
Details                                                                                                              
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Appendix 8: Short Physical Performance Battery Scoring Sheet 
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